<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Genet Mol Biol</journal-id>
<journal-id journal-id-type="iso-abbrev">Genet. Mol. Biol</journal-id>
<journal-id journal-id-type="publisher-id">gmb</journal-id>
<journal-title-group>
<journal-title>Genetics and Molecular Biology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1415-4757</issn>
<issn pub-type="epub">1678-4685</issn>
<publisher>
<publisher-name>Sociedade Brasileira de Genética</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30235399</article-id>
<article-id pub-id-type="pmc">6136378</article-id>
<article-id pub-id-type="doi">10.1590/1678-4685-GMB-2017-0235</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The microbiome and inborn errors of metabolism: Why we should look carefully at their interplay?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Colonetti</surname>
<given-names>Karina</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Roesch</surname>
<given-names>Luiz Fernando</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schwartz</surname>
<given-names>Ida Vanessa Doederlein</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<aff id="aff1">
<label><sup>1</sup></label>Programa de Pós-Graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil</aff>
<aff id="aff2">
<label><sup>2</sup></label>Laboratory of Basic Research and Advanced Investigations in Neurosciences (BRAIN), Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil</aff>
<aff id="aff3">
<label><sup>3</sup></label>Interdisciplinary Research Center on Biotechnology-CIP-Biotec, Universidade Federal do Pampa, Bagé, RS, Brazil</aff>
<aff id="aff4">
<label><sup>4</sup></label>Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil</aff>
</contrib-group>
<author-notes>
<corresp id="c1">Send correspondence to Karina Colonetti. Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2350, 90035-903 Porto Alegre, RS, Brazil. E-mail: <email>kcolonetti@gmail.com</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<season>Jul-Sep</season>
<year>2018</year>
</pub-date>
<!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
<pub-date pub-type="ppub">
<season>Jul-Sep</season>
<year>2018</year>
</pub-date>
<volume>41</volume>
<issue>3</issue>
<fpage>515</fpage>
<lpage>532</lpage>
<history>
<date date-type="received">
<day>28</day>
<month>7</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>1</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018, Sociedade Brasileira de Genética.</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
<license-p>License information: This is an open-access article distributed under the terms of the Creative Commons Attribution License (type CC-BY), which permits unrestricted use, distribution and reproduction in any medium, provided the original article is properly cited.</license-p>
</license>
</permissions>
<abstract>
<title>Abstract</title>
<p>Research into the influence of the microbiome on the human body has been shedding new light on diseases long known to be multifactorial, such as obesity, mood disorders, autism, and inflammatory bowel disease. Although inborn errors of metabolism (IEMs) are monogenic diseases, genotype alone is not enough to explain the wide phenotypic variability observed in patients with these conditions. Genetics and diet exert a strong influence on the microbiome, and diet is used (alone or as an adjuvant) in the treatment of many IEMs. This review will describe how the effects of the microbiome on the host can interfere with IEM phenotypes through interactions with organs such as the liver and brain, two of the structures most commonly affected by IEMs. The relationships between treatment strategies for some IEMs and the microbiome will also be addressed. Studies on the microbiome and its influence in individuals with IEMs are still incipient, but are of the utmost importance to elucidating the phenotypic variety observed in these conditions.</p>
</abstract>
<kwd-group>
<title>Keywords:</title>
<kwd>Inborn errors of metabolism</kwd>
<kwd>microbiome</kwd>
<kwd>microbiota</kwd>
<kwd>diet</kwd>
<kwd>treatment</kwd>
</kwd-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="2"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="158"></ref-count>
<page-count count="18"></page-count>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>The human body host a large amount of non-human genetic material, the microbiome, defined as the set of microorganisms, their genes, and the surrounding environmental conditions (<xref ref-type="bibr" rid="B80">Marchesi and Ravel, 2015</xref>). The human gut microbiome is believed to play an important role in the development of basic physiological systems, such as the digestive, immune, and nervous systems, and constitutes a virtual metabolic organ of unquestionable importance (<xref ref-type="bibr" rid="B74">Lopez-Legarrea <italic>et al.</italic>, 2014</xref>; <xref ref-type="bibr" rid="B135">Suez <italic>et al.</italic>, 2014</xref>; <xref ref-type="bibr" rid="B83">Maukonen and Saarela, 2015</xref>). The gastrointestinal (GI) tract is a metabolically rich environment that harbors approximately three-quarters of the body’s immune cells, contains vagal afferent endings which respond to immune cells and immune and bacterial products (cytokines, proteases, 5-Hydroxytryptimaine and CRH for corticotropin-releasing hotmone, CRH, histamine), and has receptors for compounds produced by neuroendocrine cells (<xref ref-type="bibr" rid="B97">Omran and Aziz, 2014</xref>). Diet and genes related to the immune system and metabolism are among the key factors with potential to alter the bacterial community present in the gut. Thus, the associations of diet, metabolism, the central nervous system, and the immune system with the development and composition of the gut microbiome has become the object of intense interest among the scientific community (<xref ref-type="bibr" rid="B84">Mayer <italic>et al.</italic>, 2014</xref>).</p>
<p>Inborn errors of metabolism (IEM) are rare monogenic genetic diseases characterized by absent or deficient activity of a given enzyme and which can sometimes be managed with dietary strategies. The phenotypic heterogeneity found in IEMs is manifested mainly by the age at onset of symptoms, presence (or absence) of neurological compromise, and response to the treatment. In untreated phenylketonuria (PKU) and in propionic and methylmalonic acidemia patients, for instance, the neurological and behavior impairment are highly variable. The development of liver disease is common to several IEMs, such as tyrosinemia type 1 and urea cycle disorders. Also, the response to the treatment is not the same among patients with the same genotype.</p>
<p>Convergent efforts of professionals in different fields have enabled the discovery of new mechanisms and processes whereby the microbiome can exert local and systemic effects. In this non-systematic review of the literature, we will focus on how the gut microbiome could influence the context of treatable IEMs.</p>
</sec>
<sec>
<title>The human gut microbiome</title>
<p>Among the various microbial habitats found in the human body, the GI tract harbors the vast majority of microbial cells (<xref ref-type="bibr" rid="B120">Sender <italic>et al.</italic>, 2016</xref>). The composition of the microbiota varies along the GI tract, both quantitatively and qualitatively, depending on the environmental conditions (pH, oxygen, etc.) (<xref ref-type="bibr" rid="B38">Donaldson <italic>et al.</italic>, 2016</xref>). In the small bowel (particularly the duodenum), the composition is similar to that of the stomach, while the large bowel (especially the colon) contains the majority of the gut’s microbial population, as it is the site of fermentation, due to the availability of nutrients obtained from digestion (<xref ref-type="bibr" rid="B79">Madigan and Martinko, 2006</xref>).</p>
<p>Prior to the development of next-generation sequencing (NGS) techniques, the gene profile of these microorganisms had never been determined accurately (<xref ref-type="bibr" rid="B50">Grenham <italic>et al.</italic>, 2011</xref>). The ability to obtain a large number of gene sequences in a short period of time and at relatively low cost led to the acquisition of an immense volume of data to which biological significance could then be ascribed (<xref ref-type="bibr" rid="B23">Cho and Blaser, 2012</xref>). Advances in these techniques, coupled with the development of bioinformatics tools, have allowed analysis of the gut microbiome to an extent that would have been impossible with bacterial cultures alone (<xref ref-type="bibr" rid="B55">Hiergeist <italic>et al.</italic>, 2015</xref>). Furthermore, the use of NGS and bioinformatics techniques, with the aid of databases and computational and statistical algorithms, has allowed complex studies for the detection, quantification, and functional analysis of the human microbiome and its physiological associations, thus expanding knowledge of microbial ecology beyond simple pathogen <italic>vs.</italic> host relationships.</p>
<p>Initiatives such as the Human Microbiome Project, created in the United States in 2008, have sought to characterize the microbial communities of various sites in the human body, with a focus on analyzing the role of these microorganisms in sickness and in health (<xref ref-type="bibr" rid="B57">Human Microbiome Project Consortium, 2012</xref>). In Europe, a similar effort known as <xref ref-type="bibr" rid="B153">MetaHIT</xref>, which took place from 2008 to 2012, sought to study the association of the gut microbiome with several states of health and illness, prioritizing obesity and inflammatory bowel disease (Metagenomics of the Human Intestinal Tract, MetaHIT.</p>
<p>The results of the aforementioned initiatives have led to a new appreciation for the human microbiome from taxonomic and functional points of view. The microbiota is both functionally relevant and uniquely personal, differing even between monozygotic twins, what suggests that childhood exposure to different environmental factors is a determinant of development of the adult microbiota (<xref ref-type="bibr" rid="B139">Turnbaugh and Gordon, 2009</xref>). Despite great interpersonal variation in the microbiota, the metabolic roles of its microorganisms are highly conserved: enriching the biosynthesis of cofactors and vitamins, in addition to a key role in central carbohydrate metabolism, aromatic amino acids (AA), and ATP synthesis in the lower GI tract (<xref ref-type="bibr" rid="B119">Segata <italic>et al.</italic>, 2011</xref>; <xref ref-type="bibr" rid="B57">Human Microbiome Project Consortium, 2012</xref>). This has given rise to the notion of a “functional core” of microorganisms rather than a core set of microbial taxa, as the same essential roles can be played by different taxa (<xref ref-type="bibr" rid="B73">Lloyd-Price <italic>et al.</italic>, 2016</xref>).</p>
<p>The gut microbiota is influenced by the environment and affected by diet, medications, age, geographic factors, surgical interventions, and host genetics, particularly genes related to the immune system and metabolism (<xref ref-type="bibr" rid="B148">Yatsunenko <italic>et al.</italic>, 2012</xref>; <xref ref-type="bibr" rid="B31">Dabrowska and Witkiewicz, 2016</xref>; <xref ref-type="bibr" rid="B48">Goodrich <italic>et al.</italic>, 2016</xref>). The gut microbiome suffers drastic changes during the first three years of life (<xref ref-type="bibr" rid="B148">Yatsunenko <italic>et al.</italic>, 2012</xref>). After that, diet is one of the main factors that shape the gut microbiota (<xref ref-type="bibr" rid="B35">De Filippo <italic>et al.</italic>, 2010</xref>; <xref ref-type="bibr" rid="B33">David <italic>et al.</italic>, 2014</xref>), and the microbiome continues to evolve all lifelong (<xref ref-type="bibr" rid="B99">Ottman <italic>et al.</italic>, 2012</xref>; <xref ref-type="bibr" rid="B96">Odamaki <italic>et al.</italic>, 2016</xref>). Once diet is strongly correlated with cultural habits and is affected by geographic factors, such as availability of nutrients and source of carbohydrates, fibers and fat, one can also consider that culture affects the patterns found in the microbiome (<xref ref-type="bibr" rid="B148">Yatsunenko <italic>et al.</italic>, 2012</xref>). To study the microbiome is also to study ecology. From an ecological point of view, maintaining sufficient bacterial diversity and richness is important for gut microbiota functional redundancy, adaptability and to provide a certain tolerance against environmental challenges, resilience (<xref ref-type="bibr" rid="B47">Gill <italic>et al.</italic>, 2006</xref>). Western diets, rich in calories and refined sugar, are associated with lower richness in microbial communities at individual level (alpha diversity) and higher variation among individuals (beta diversity) when compared with diets high in fiber and relatively low in calories (<xref ref-type="bibr" rid="B81">Martínez <italic>et al.</italic>, 2015</xref>). Individuals who consume a Western type diet with high-energy and high-fat intake present changes in metabolic and immune biomarkers, such as a higher body mass index and higher levels of inflammatory markers than those who follow a high-fiber, low-calorie diet (<xref ref-type="bibr" rid="B18">Cani <italic>et al.</italic>, 2009</xref>). Taken together, these facts have led to associations between microbial richness and health. Once microbial richness is strongly associated with diet patterns (<xref ref-type="bibr" rid="B35">De Filippo <italic>et al.</italic>, 2010</xref>; <xref ref-type="bibr" rid="B28">Cotillard <italic>et al.</italic>, 2013</xref>; <xref ref-type="bibr" rid="B129">Sonnenburg and Sonnenburg 2014</xref>), both the composition and energy content of one’s diet are important modulators of the microbiota (<xref ref-type="bibr" rid="B98">Oriach <italic>et al.</italic>, 2016</xref>). Diet is a crucial driver of the composition of the microbial community from childhood to old age (<xref ref-type="bibr" rid="B62">Kashtanova <italic>et al.</italic>, 2016</xref>) and has the potential to alter the bacterial metabolite profile, thus influencing the host’s metabolism both directly and indirectly.</p>
<p>The major bacterial metabolites known to influence the host include short-chain fatty acids (SCFAs) and vitamins. SCFAs are organic monocarboxylic acids with six or fewer carbon atoms, generated by anaerobic fermentation of indigestible dietary fibers (such as cellulose, xylans, and inulin) in the gut. The main SCFAs produced as a result of these fermentation processes are butyrate, acetate, and propionate. SCFAs are absorbed by the host and are important energy sources, corresponding to 10% of the energy source in a Western diet. Portal and hepatic veins contain large amounts of SCFAs (<xref ref-type="bibr" rid="B30">Cummings <italic>et al.</italic>, 1987</xref>). SCFAs also stimulate growth of bacteria in the genera <italic>Lactobacillus</italic> and <italic>Bifidobacterium</italic>, these playing a key role in colon physiology and metabolism (<xref ref-type="bibr" rid="B112">Roy <italic>et al.</italic>, 2006</xref>) and influencing the immune and inflammatory responses (<xref ref-type="bibr" rid="B82">Maslowski and Mackay, 2011</xref>; <xref ref-type="bibr" rid="B138">Tremaroli and Bäckhed, 2012</xref>; <xref ref-type="bibr" rid="B74">Lopez-Legarrea <italic>et al.</italic>, 2014</xref>). <italic>In vitro</italic>, SCFAs increase the production of anti-inflammatory cytokines, such as IL-10, and decrease production of proinflammatory cytokines, such as IL-1β, IL-6, and TNF-α (<xref ref-type="bibr" rid="B141">Vinolo <italic>et al.</italic>, 2011</xref>). Production of SCFAs also promotes transcription of the <italic>PTH1</italic> gene, which encodes tryptophan hydroxylase, the rate-limiting enzyme of serotonin synthesis in the gut (<xref ref-type="bibr" rid="B108">Reigstad <italic>et al.</italic>, 2015</xref>). SCFAs are also generally involved in G-protein signaling, modulation of cell signaling, cell–cell interactions, gene expression, immune function, and neurotransmitter synthesis and release (<xref ref-type="bibr" rid="B89">Nakao <italic>et al.</italic>, 1998</xref>; <xref ref-type="bibr" rid="B67">Le Poul <italic>et al.</italic>, 2003</xref>; <xref ref-type="bibr" rid="B94">Nguyen <italic>et al.</italic>, 2007</xref>; <xref ref-type="bibr" rid="B53">Han <italic>et al.</italic>, 2014</xref>; <xref ref-type="bibr" rid="B90">Nankova <italic>et al.</italic>, 2014</xref>). Several physiological effects, including regulation of energy homeostasis, obesity, immune system functions, cancer, and cerebral function, as well as histone deacetylase (HDAC) inhibition, have been associated with butyrate (<xref ref-type="bibr" rid="B64">Koh <italic>et al.</italic>, 2016</xref>). Specific host transporters and receptors are available for butyrate, and it is also used by colon cells as a source of energy through beta-oxidation (<xref ref-type="bibr" rid="B133">Stilling <italic>et al.</italic>, 2016</xref>). Furthermore, acetate and propionate can be used by the liver for lipogenesis and gluconeogenesis, respectively (<xref ref-type="bibr" rid="B59">Janssen and Kersten, 2015</xref>). The potential for modulation of host metabolism and genetics by the gut microbiota suggests that the role of this factor warrants closer attention. This is especially true in IEMs in which metabolic pathways are originally altered, as the microbiome may act to reinforce metabolic pathways that are advantageous or disadvantageous to the host, with a direct impact on phenotype.</p>
<p>The evidence for a role of the composition of the human gut microbiota and its metabolites in health and illness becomes increasingly stronger (<xref ref-type="bibr" rid="B123">Sharon <italic>et al.</italic>, 2014</xref>; <xref ref-type="bibr" rid="B27">Coleman and Nunes, 2016</xref>; <xref ref-type="bibr" rid="B109">Rooks and Garrett, 2016</xref>). Changes in the GI tract microbiota induce metabolic changes with systemic effects (<xref ref-type="bibr" rid="B138">Tremaroli and Bäckhed, 2012</xref>; <xref ref-type="bibr" rid="B95">Ochoa-Repáraz and Kasper, 2014</xref>; <xref ref-type="bibr" rid="B123">Sharon <italic>et al.</italic>, 2014</xref>), and current research seeks to characterize microbiota–host interactions to elucidate the depth and breadth of this influence.</p>
<p>Some conditions, such as liver and bowel diseases and <italic>Clostridium difficile</italic> infection, are already being treated with microbiota-modifying therapies. These include probiotics, prebiotics, antibiotics, and fecal transplant (<xref ref-type="bibr" rid="B125">Sheth <italic>et al.</italic>, 2016</xref>; <xref ref-type="bibr" rid="B149">Young, 2017</xref>). Probiotics are living microorganisms that, when administered at an appropriate concentration, can confer health benefits to the host, while prebiotics are indigestible components of foods that benefit the host by promoting growth or activity of a specific bacterial species or community in the colon. Fecal transplant is the administration of fecal matter from a healthy donor to a diseased individual, with the objective of restoring the typical microbial community of the healthy gut. These strategies can be used jointly or in isolation to restore the balance of the intestinal microbial community in the event of dysbiosis, which is any change to the composition of resident commensal communities relative to the community found in healthy individuals.</p>
</sec>
<sec>
<title>Inborn Errors of Metabolism (IEM)</title>
<p>IEMs are individually rare diseases, but as a group they are fairly common. Currently, more than 600 known human diseases are classified as IEMs (<xref ref-type="bibr" rid="B1">Alfadhel <italic>et al.</italic>, 2016</xref>). Classically, IEMs are defined as a set of monogenic (single-gene) diseases that cause protein dysfunction, with partial or total loss of enzyme activity; however, IEMs can be pleiotropic, and may involve virtually any organ or system. Clinical onset may occur from even before birth up to adulthood (<xref ref-type="bibr" rid="B122">Sharer, 2011</xref>), and environmental triggers may be crucial determinants of individual phenotype (<xref ref-type="bibr" rid="B65">Lanpher <italic>et al.</italic>, 2006</xref>). In an individual IEM, one primary metabolite flux is affected. In complex disease, however, a whole network of metabolite fluxes might be subtly altered to contribute to the overall phenotype. This concept of metabolic flux is essential in the translation of genetic and environmental factors into the phenotype or threshold for disease (<xref ref-type="bibr" rid="B65">Lanpher <italic>et al.</italic>, 2006</xref>). Even a single metabolite defect can affect several secondary metabolic pathways, with a greater or lesser degree of environmental influence, to contribute to each patient’s specific phenotype.</p>
<p>The treatment and management of IEMs are always individualized, based on each patient’s diagnosis and phenotype, and there is broad heterogeneity even within each category (<xref ref-type="bibr" rid="B2">Argmann <italic>et al.</italic>, 2016</xref>). Despite this heterogeneity in management approaches, the specific treatment usually falls into one of three classes: (I) enzyme replacement therapy, to replenish the deficient enzyme; (II) substrate reduction therapy; or (III) dietary treatment, although organ transplantation is also used in some cases (<xref ref-type="bibr" rid="B41">Ezgu, 2016</xref>). Additional non-specific treatment may be necessary, depending on the presence of comorbidities, such as neuropsychiatric disorders in PKU patients (<xref ref-type="bibr" rid="B10">Bilder <italic>et al.</italic>, 2017</xref>), or renal and neurologic impairment in patients with tyrosinemia type I (<xref ref-type="bibr" rid="B116">Santra <italic>et al.</italic>, 2008</xref>; <xref ref-type="bibr" rid="B21">Chinsky <italic>et al.</italic>, 2017</xref>). Given the importance of diet to the microbiome, we will primarily address dietary therapy in this review, with a secondary focus on the importance of the microbiome in allogeneic hematopoietic stem-cell transplantation (HSCT).</p>
<p>Dietary treatment for IEMs may be employed as monotherapy or adjuvant therapy. Its purpose is to eliminate or reduce whichever toxic compound that accumulates in the body (<xref ref-type="bibr" rid="B118">Schwartz <italic>et al.</italic>, 2008</xref>). However, this form of therapy has several limitations, including overload and/or deficiency of certain food groups and nutrients (<xref ref-type="bibr" rid="B29">Crenn and Maillot, 2007</xref>; <xref ref-type="bibr" rid="B13">Boyer <italic>et al.</italic>, 2015</xref>). Theoretically, diets restricted or excessively rich in certain nutrients may prompt a state of intestinal dysbiosis with systemic effects, leading to malnutrition, obesity (<xref ref-type="bibr" rid="B54">Henao-Mejia <italic>et al.</italic>, 2012</xref>), type 1 (<xref ref-type="bibr" rid="B143">Wen <italic>et al.</italic>, 2008</xref>) or type 2 diabetes (<xref ref-type="bibr" rid="B66">Larsen <italic>et al.</italic>, 2010</xref>), inflammatory bowel disease (<xref ref-type="bibr" rid="B3">Ashton <italic>et al.</italic>, 2017</xref>; <xref ref-type="bibr" rid="B45">Geirnaert <italic>et al.</italic>, 2017</xref>) and liver disease (<xref ref-type="bibr" rid="B69">Lee and Sokol, 2015</xref>), as well as a variety of disorders featuring an inflammatory component, symptoms of autism spectrum disorders (<xref ref-type="bibr" rid="B34">De Angelis <italic>et al.</italic>, 2015</xref>), and even cancer (<xref ref-type="bibr" rid="B58">Jacqueline <italic>et al.</italic>, 2017</xref>; <xref ref-type="bibr" rid="B146">Xu and Jiang, 2017</xref>). Studies seeking to identify the effects of dietary treatment and nutrient supplementation on the microbiome of patients with IEMs are still scarce. A summary of this research will be presented below and in <xref ref-type="table" rid="t1">Table 1</xref>.</p>
<table-wrap id="t1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<title>Inborn errors of metabolism addressed in this review, main phenotypic features, and overview of management.</title>
</caption>
<table frame="hsides" rules="groups">
<colgroup span="1" width="20%">
<col span="1"/>
<col span="1"/>
<col span="1"/>
<col span="1"/>
<col span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">EIM (Substrate accumulated)</th>
<th align="left" colspan="1" rowspan="1">Affected protein/gene</th>
<th align="left" colspan="1" rowspan="1">Main clinical features</th>
<th align="left" colspan="1" rowspan="1">Long-term management</th>
<th align="left" colspan="1" rowspan="1">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1" valign="top">Phenylketonuria (Phenylalanine)</td>
<td colspan="1" rowspan="1" valign="top">Phenylalanine-4-hydroxylase (<italic>PAH</italic>)</td>
<td colspan="1" rowspan="1" valign="top">Neurologic impairments, with physical, cognitive, and behavioral consequences, even in well-controlled PKU</td>
<td colspan="1" rowspan="1" valign="top">Restriction of dietary phenylalanine. Phe-free medical formula.<break></break>Sapropterin (BH<sub>4</sub>) supplementation in responsive patients.<break></break>Large neutral amino acids (LNAA)</td>
<td colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B156">Regier and Greene, 2000</xref>; OMIM #261600</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Tyrosinemia type I (Tyrosine, maleylacetoacetate, fumarylacetoacetate, and succinylacetone)</td>
<td colspan="1" rowspan="1" valign="top">Fumarylacetoacetate hydrolase (<italic>FAH</italic>)</td>
<td colspan="1" rowspan="1" valign="top">Hepatomegaly, acute liver failure, cirrhosis and hepatocellular carcinoma<break></break>Episodic paralysis and episodic peripheral neuropathy<break></break>Renal Fanconi syndrome, renal failure, glomerulosclerosis, nephromegaly, nephrocalcinosis<break></break>Gastrointestinal bleeding, paralytic ileus<break></break>Pancreatic islet-cell hypertrophy, splenomegaly<break></break>Rickets, chronic weakness</td>
<td colspan="1" rowspan="1" valign="top">Dietary management with reduced intake of phenylalanine and tyrosine;<break></break>Nitisinone<break></break>Liver transplantation</td>
<td colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B32">Das, 2017</xref>; <xref ref-type="bibr" rid="B157">Sniderman et al., 2006</xref>; OMIM #276700</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Urea cycle disorders (Ammonia)</td>
<td colspan="1" rowspan="1" valign="top">Carbamoylphosphate synthetase I (<italic>CPS1</italic>); Ornithine transcarbamylase deficiency (<italic>OTC</italic>); Argininosuccinate Synthase 1 (<italic>ASS1</italic>); Argininosuccinate lyase (<italic>ASL</italic>), Arginase-1 (<italic>ARG1</italic>); N-acetylglutamate synthase (<italic>NAGS</italic>); Ornithine transporter (<italic>SLC25A15</italic>); or citrin (<italic>SLC25A13</italic>)</td>
<td colspan="1" rowspan="1" valign="top">Vomiting, lethargy, and behavioral abnormalities.<break></break>Neurologic impairments. Seizures in acute hyperammonemia.<break></break>Liver impairments</td>
<td colspan="1" rowspan="1" valign="top">Dietary management with reduced intake of proteins,<break></break>Essential amino acids supplementation.<break></break>Vitamin and mineral supplementation,<break></break>Medications to increase the nitrogen excretion.<break></break>Liver transplantation,</td>
<td colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B151">Ah Mew et al., 2003</xref>; <xref ref-type="bibr" rid="B52">Häberle et al., 2012</xref>.</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Alkaptonuria (Homogentisic acid and its oxidation products)</td>
<td colspan="1" rowspan="1" valign="top">Homogentisate 1, 2-dioxygenase (<italic>HGD</italic>)</td>
<td colspan="1" rowspan="1" valign="top">Urine that turns dark on standing, alkalinization, black ochronotic pigmentation of cartilage and collagenous tissues, arthritis (especially in the spine).<break></break>Cardiovascular impairments: Aortic and/or mitral valve calcification, coronary artery calcification, aortic dilatation.<break></break>Urolithiasis, ochronotic prostate stones (in males)</td>
<td colspan="1" rowspan="1" valign="top">Nitisinone <xref ref-type="table-fn" rid="TFN1">
<sup>*</sup>
</xref>
</td>
<td colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B152">Introne and Gahl, 2003</xref>; <xref ref-type="bibr" rid="B86">Mistry et al., 2013</xref>; <xref ref-type="bibr" rid="B154">OMIM</xref> #203500</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Propionic acidemia (Propionic acid)</td>
<td colspan="1" rowspan="1" valign="top">Propionyl-CoA carboxylase (<italic>PCC</italic>)</td>
<td align="left" colspan="1" rowspan="1">Central nervous system impairments: acute encephalopathy, lethargy, axial hypotonia, limb hypertonia, coma, seizure, psychomotor retardation, cerebral atrophy, dystonia, cerebellar hemorrhage (rare), ischemic stroke in the basal ganglia (rare).<break></break>Decreased appetite, feeding difficulties, vomiting, dehydration.<break></break>Hepatomegaly, pancreatitis.<break></break>Pancytopenia, neutropenia, anemia, thrombocytopenia. Cardiomyopathy, tachypnea, apnea.<break></break>Osteoporosis, dermatitis acidemica</td>
<td colspan="1" rowspan="1" valign="top">L-carnitine,<break></break>Antibiotics,<break></break>Low-protein diet,<break></break>Vitamin and mineral supplementation, Precursor-free amino acid and/or isoleucine/ valine supplementation.</td>
<td colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B8">Baumgartner et al., 2014</xref>; OMIM #606054<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180313/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180313/</ext-link>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Methylmalonic Acidemia (Methylmalonic acid)</td>
<td colspan="1" rowspan="1" valign="top">Methylmalonyl-CoA mutase (<italic>MUT</italic>)</td>
<td colspan="1" rowspan="1" valign="top">Central nervous system impairments: lethargy, hypotonia, developmental delay, coma, severe involvement of globus pallidus, delay in myelination, cerebellar hemorrhage (rare), ischemic stroke in the basal ganglia (rare)}. Leukopenia, thrombocytopenia.<break></break>Cardiomyopathy, hepatomegaly, pancreatitis, recurrent episodes of vomiting, interstitial nephritis, chronic renal failure</td>
<td colspan="1" rowspan="1" valign="top">Same as in PA, plus vitamin B12 in responsive patients.</td>
<td colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B8">Baumgartner et al., 2014</xref>; OMIM #251000</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Hemochromatosis type 1 (Iron)</td>
<td colspan="1" rowspan="1" valign="top">HFE protein, Hemochromatosis gene (<italic>HFE1</italic>)</td>
<td colspan="1" rowspan="1" valign="top">Heart involvement: cardiomyopathy, congestive heart failure, arrhythmia, cardiomegaly.<break></break>Liver involvement: cirrhosis, hepatomegaly, hepatocellular carcinoma.<break></break>Diabetes mellitus.<break></break>Arthritis.<break></break>Hypogonadotropic hypogonadism.<break></break>The severe effects of the disease usually do not appear until after decades of progressive iron loading</td>
<td colspan="1" rowspan="1" valign="top">Periodic phlebotomy</td>
<td colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B158">Seckington and Powell, 2000</xref>; OMIM #235200</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Trimethylaminuria (Amino-trimethylamine)</td>
<td colspan="1" rowspan="1" valign="top">Flavin-containing monooxygenase 3 (<italic>FMO3</italic>)</td>
<td colspan="1" rowspan="1" valign="top">Behavioral/psychiatric manifestations: depression, suicidal, psychosocial problems in school. In some patients: anemia, neutropenia, pulmonary infections; tachycardia and severe hypertension after eating cheese.</td>
<td colspan="1" rowspan="1" valign="top">Dietary restriction of: Trimethylamine and its precursors including choline and lecithin Trimethylamine N-oxide; Inhibitors of FMO3 enzyme activity, such as indoles. Use of: acid soaps and body lotions, activated charcoal and copper chlorophyllin, antibiotics, riboflavin supplements.</td>
<td colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B155">Phillips and Shephard, 2007</xref>; OMIM #602079</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN1">
<label>*</label>
<p>Under investigation</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Organ transplantation (mainly liver transplantation and HSCT) is also a treatment option for several IEMs (<xref ref-type="bibr" rid="B126">Sirrs <italic>et al.</italic>, 2013</xref>; <xref ref-type="bibr" rid="B11">Boelens <italic>et al.</italic>, 2014</xref>). Within this context, the microbiome was recently noted as a key factor in graft-<italic>vs.</italic> -host disease (GVHD). Acute GVHD is characterized by rupture of the intestinal barrier, caused by the conditioning regimen administered before HSCT and by leakage of microbe-associated molecular patterns (MAMPs, also known as pathogen-associated molecular patterns or PAMPs), particularly lipopolysaccharide (LPS). The proinflammatory response mounted against these molecules leads to systemic inflammation. Antibiotic treatment in the perioperative period of allogeneic HSCT has been associated with a higher likelihood of GVHD and lower odds of survival, which suggests a potentially pathogenic role of antibiotics through depletion of gut microbiome diversity. The finding that fecal transplant successfully treats GVHD by reconstituting the microbiota has reinforced this theory (<xref ref-type="bibr" rid="B6">Balmer <italic>et al.</italic>, 2014</xref>; <xref ref-type="bibr" rid="B85">Melis <italic>et al.</italic>, 2014</xref>; <xref ref-type="bibr" rid="B61">Kakihana <italic>et al.</italic>, 2016</xref>; <xref ref-type="bibr" rid="B106">Rashidi <italic>et al.</italic>, 2017</xref>; <xref ref-type="bibr" rid="B110">Routy <italic>et al.</italic>, 2017</xref>; <xref ref-type="bibr" rid="B130">Spindelboeck <italic>et al.</italic>, 2017</xref>). Efforts to characterize the influence of the microbiome in complications resulting from organ transplantation are paving the way for new avenues of treatment. Administration of <italic>Lactobacillus</italic>, for instance, appears to be a promising strategy for treatment of GVHD in allogeneic HSCT recipients, although the mechanism of action has yet to be fully understood (<xref ref-type="bibr" rid="B131">Staffas <italic>et al.</italic>, 2017</xref>).</p>
</sec>
<sec>
<title>Influence of the microbiome on the major organs affected by IEMs</title>
<p>The features of IEMs are highly heterogeneous; however, the nervous system central (CNS) and liver, due to their high metabolic rate, are particularly susceptible to the effects of any metabolic defect (<xref ref-type="bibr" rid="B113">Sahoo <italic>et al.</italic>, 2012</xref>). These organs are also closely related to microbiome activity, and a summary of on this matter can be found in <xref ref-type="fig" rid="f1">Figure 1</xref>.</p>
<fig id="f1" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<title>Known effects of the gut microbiome on the main organs affected in an IEM. In bold are the ways by which the interactions occur. Below are the features related to the gut microbiota and the organs. The gut microbiome produces several metabolites and actively participates in the biosynthesis of vitamins and cofactors, metabolism of carbohydrates, proteins and lipids. The gut microbiota interacts with the whole body via the immune and endocrine systems. The two major organs affected in an IEM are the brain and the liver. In addition to the components of the immune and endocrine systems, the described gut-brain interactions also involve the brain-blood barrier, HPA axis, vagus nerve and the sympathetic system. This may predispose to several diseases, such as increased cardiovascular risk, multiple sclerosis, Alzheimer’s disease, depression, autism, anxiety, and also can be related to pain. Interactions with the liver can occur via the portal vein, the gut-blood barrier, and can be involved in several hepatic diseases, most of them linked to endotoxemia.</title>
</caption>
<graphic xlink:href="1415-4757-GMB-41-03-2017-0235-gf01"></graphic>
</fig>
<p>The microbiome has wide-ranging influence on the CNS, with probable effects on metabolism (<xref ref-type="bibr" rid="B44">Fu <italic>et al.</italic>, 2015</xref>; <xref ref-type="bibr" rid="B88">Montagner <italic>et al.</italic>, 2016</xref>), coordination (<xref ref-type="bibr" rid="B114">Sampson <italic>et al.</italic>, 2016</xref>), mood (<xref ref-type="bibr" rid="B127">Slykerman <italic>et al.</italic>, 2017</xref>), behavior (<xref ref-type="bibr" rid="B137">Tillisch <italic>et al.</italic>, 2013</xref>), cognition (<xref ref-type="bibr" rid="B132">Steenbergen <italic>et al.</italic>, 2015</xref>), temperature control (<xref ref-type="bibr" rid="B20">Chevalier <italic>et al.</italic>, 2015</xref>), and sensation (<xref ref-type="bibr" rid="B22">Chiu <italic>et al.</italic>, 2013</xref>). This influence may begin before birth, via the maternal microbiome (<xref ref-type="bibr" rid="B107">Rautava <italic>et al.</italic>, 2012</xref>), and may be perpetuated throughout life, playing essential roles in the development of the blood–brain barrier (<xref ref-type="bibr" rid="B14">Braniste <italic>et al.</italic>, 2014</xref>), maturation of the immune system (<xref ref-type="bibr" rid="B25">Chung <italic>et al.</italic>, 2012</xref>), and also myelination of the prefrontal cortex (<xref ref-type="bibr" rid="B56">Hoban <italic>et al.</italic>, 2016</xref>). Communication between the microbiome and the CNS is two-way, occurring both through metabolites and toxins produced by the bacterial community on the one hand, and via the immune, metabolic, nervous, and endocrine systems on the other (<xref ref-type="bibr" rid="B105">Powell <italic>et al.</italic>, 2017</xref>). Over the years, disruption of the microbiome-brain-gut axis has been associated with various diseases. A breach in system homeostasis may occur at any point along this axis. Stressful situations affecting the brain, for instance, may affect the gut microbiome via the hypothalamic-pituitary-adrenal (HPA) axis, with repercussions for immune cell activity and bowel function (<xref ref-type="bibr" rid="B87">Moloney <italic>et al.</italic>, 2014</xref>). Bacterial components, in turn, can stimulate secretion of proinflammatory cytokines from epithelial cells, dendritic cells, and macrophages. Knowingly, several neuropsychiatric disorders, including depression, anxiety, schizophrenia, and autism spectrum disorders, are associated with elevated circulating levels of proinflammatory cytokines (<xref ref-type="bibr" rid="B72">Liu <italic>et al.</italic>, 2015a</xref>; <xref ref-type="bibr" rid="B102">Petra <italic>et al.</italic>, 2015</xref>). In addition to these pathways, cerebral function can also be modulated by microbial metabolites capable of crossing the blood–brain barrier (<xref ref-type="bibr" rid="B70">Li and Zhou, 2016</xref>). <xref ref-type="bibr" rid="B103">Pierre and Pellerin (2005)</xref> reported that monocarboxylate transporters (MCTs), which transport lactate, pyruvate, ketone bodies, and other SCFAs, are widely expressed in cerebral tissue, and especially so in the cortex, hippocampus, striatum, and cerebellum (<xref ref-type="bibr" rid="B103">Pierre and Pellerin, 2005</xref>). In rats, G protein-coupled receptors (GPCRs) activated by propionic acid (PPA) are also highly expressed in brain tissue (<xref ref-type="bibr" rid="B12">Bonini <italic>et al.</italic>, 1997</xref>). Antibiotic therapy, which is commonly used in the treatment of some IEMs, depletes the microbiome and can affect levels of neuromodulatory substances (tryptophan, monoamines, and neuropeptides), thus influencing anxiety and cognition patterns (<xref ref-type="bibr" rid="B37">Desbonnet <italic>et al.</italic>, 2015</xref>).</p>
<p>As evidence mounts for a systemic effect of the gut microbiome on the host, the liver has also been found to be affected by changes in the microbiome. In addition to its central role in intermediary metabolism (for instance, many enzymes affected by IEM are only expressed in liver) and bile secretion, the liver is the target organ of therapies for metabolic disorders (<xref ref-type="bibr" rid="B16">Brunetti-Pierri and Lee, 2005</xref>) and can also be considered a secondary lymphoid organ (<xref ref-type="bibr" rid="B78">Macpherson <italic>et al.</italic>, 2016</xref>). Changes in liver physiology are probably caused primarily by DNA methylation processes, covalent histone modifications, and regulation of gene expression by non-coding RNA (<italic>nc</italic>RNA) (<xref ref-type="bibr" rid="B78">Macpherson <italic>et al.</italic>, 2016</xref>). In addition to SCFAs, isothiocyanates and polyphenols are also produced by the microbiome, and all of these compounds have the potential to cause epigenetic changes. As the liver receives blood from the gut through the portal vein, it is susceptible to exposure to microbial byproducts that cross the intestinal barrier. In humans and non-human animals alike, whenever liver or bowel disease causes dysfunction of the barrier role played by these organs, there is a breakdown in mutualism between the host and the microbiome, which leads to systemic exposure to gut bacteria and increased immune activation (<xref ref-type="bibr" rid="B19">Chassaing <italic>et al.</italic>, 2015</xref>). In these situations, the liver becomes a primary immune barrier that mediates host–microbiome mutualism (<xref ref-type="bibr" rid="B6">Balmer <italic>et al.</italic>, 2014</xref>).</p>
<p>Hepatocytes are sensitive to microbial byproducts, and may trigger an inflammatory immune response with systemic effects: even exposure to low levels of LPS induces IFN-γ overexpression and IL-10 underexpression in the liver in animal models of obesity, thus predisposing to the development of steatohepatitis (<xref ref-type="bibr" rid="B147">Yang <italic>et al.</italic>, 1997</xref>). On the other hand, deletion of the flagellin receptor TLR5 in mouse hepatocytes has been shown to predispose to hepatic steatosis and fibrosis, as well as other features of the metabolic syndrome. In this study, antibiotic treatment was able to reverse steatosis and related aspects in TLR5 knockout mice, suggesting that mechanisms for clearance of microorganisms capable of gut–liver translocation is essential for maintenance of host systemic health, preventing the chronic inflammation induced by microbial pathogens (<xref ref-type="bibr" rid="B40">Etienne-Mesmin <italic>et al.</italic>, 2016</xref>). Taking into account the important immune role of the liver, it makes sense that most patients with cirrhosis and severe liver failure die of sepsis, not of metabolic derangements (<xref ref-type="bibr" rid="B68">Leber <italic>et al.</italic>, 2009</xref>), as many of these infections are caused by oral commensals or gut microbiota (<xref ref-type="bibr" rid="B51">Gustot <italic>et al.</italic>, 2009</xref>). The dysbiosis state itself impulses inflammatory response and has potential for causing disease. The role of the microbiome in liver disorders is further supported by the efficiency of treating these conditions with probiotics, prebiotics, and antibiotics. Studying the microbiome, hence, may provide a better understanding of complex diseases and lay the groundwork for new therapies (<xref ref-type="bibr" rid="B136">Tilg <italic>et al.</italic>, 2016</xref>).</p>
</sec>
<sec>
<title>The microbiome and IEMs: the state of the art</title>
<p>The gut microbiome plays roles in amino acid and carbohydrate metabolism, vitamin and cofactor biosynthesis, and production of SCFAs, in addition to influencing the physiology of the liver, brain, and GI tract, all of which are affected by IEMs. In light of the many important activities of this virtual metabolic organ and its vast impact on the host, some studies have considered the microbiome as a factor that interferes with organic homeostasis in the context of IEMs, and have sought to characterize possible interactions, both endogenous (genetic defect) and exogenous (treatment/diet), with host metabolic pathways, as well as the probable consequences of the presence or absence of specific bacteria and their metabolites on the human body.</p>
<p>Studies of the association between microbiome and IEMs have focused on aminoacidopathies (such as PKU, tyrosinemia, and alkaptonuria), organic acidemias (methylmalonic acidemia and propionic acidemia), and hemochromatosis. The main characteristics of the IEMs addressed in these studies, including their long-term management, are summarized in <xref ref-type="table" rid="t2">Table 2</xref>. Some possible effects of treatments of IEM on microbiome are showed in <xref ref-type="fig" rid="f2">Figure 2</xref>.</p>
<table-wrap id="t2" orientation="portrait" position="float">
<label>Table 2</label>
<caption>
<title>Summary of experimental studies addressing the role of the microbiome in inborn errors of metabolism.</title>
</caption>
<table frame="hsides" rules="groups">
<colgroup span="1" width="17%">
<col span="1"/>
<col span="1"/>
<col span="1"/>
<col span="1"/>
<col span="1"/>
<col span="1"/>
</colgroup>
<thead>
<tr>
<th colspan="1" rowspan="1" valign="top">Reference</th>
<th colspan="1" rowspan="1" valign="top">EIM</th>
<th colspan="1" rowspan="1" valign="top">Model</th>
<th colspan="1" rowspan="1" valign="top">Experimental design</th>
<th colspan="1" rowspan="1" valign="top">Aims</th>
<th colspan="1" rowspan="1" valign="top">Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B93">Ney et al., 2017</xref>
</td>
<td colspan="1" rowspan="1" valign="top">Phenylketonuria</td>
<td colspan="1" rowspan="1" valign="top">Human</td>
<td colspan="1" rowspan="1" valign="top">Randomized, controlled, crossover trial;<break></break>Early-treated PKU subjects consumed, for 3-wk. each, their usual low-Phe diet combined with AA-Formula or GMP;<break></break>Metabolomics analysis of a subset of plasma and 24-h urine samples;<break></break>Dietary intake.</td>
<td colspan="1" rowspan="1" valign="top">To assess metabolites and neurotransmitters derived from Tyr and Trp in plasma and urine samples from subjects with PKU consuming both AA-formula and GMP</td>
<td colspan="1" rowspan="1" valign="top">Plasma metabolome: 7 of the 40 microbiome-associated compounds showed differential levels with AA-formula compared with GMP;<break></break>Significant differences in the plasma profile of secondary bile acids;<break></break>Associated compounds showed differential levels with AA-Formula compared with GMP;<break></break>Urine metabolome: 7 of 45 microbiome; Individuals fed with AA formula had a 50% higher intake of Tyr and Trp;<break></break>Differential degradation level of Tyr by intestinal microbes of individuals fed with AA-formula, potential harmful metabolites formed;<break></break>Higher metabolism of Trp via the kynurenine pathway might be linked with inflammation patterns;</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top"></td>
<td colspan="1" rowspan="1" valign="top"></td>
<td colspan="1" rowspan="1" valign="top"></td>
<td colspan="1" rowspan="1" valign="top"></td>
<td colspan="1" rowspan="1" valign="top"></td>
<td colspan="1" rowspan="1" valign="top">Reinforces prebiotic properties of GMP.</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B104">Pinheiro de Oliveira et al., 2016</xref>
</td>
<td colspan="1" rowspan="1" valign="top">Phenylketonuria</td>
<td colspan="1" rowspan="1" valign="top">Human</td>
<td colspan="1" rowspan="1" valign="top">Observational, cross-sectional study, convenience sampling strategy;<break></break>Review of medical records for Plasma Phe and Tyr levels, and daily Phe intake;<break></break>Questionnaire including questions on comorbidities, use of medicines, and dietary intake;<break></break>V4-16S rRNA gene sequencing; Metagenome prediction.</td>
<td colspan="1" rowspan="1" valign="top">To characterize the microbiome of PKU patients</td>
<td colspan="1" rowspan="1" valign="top">Decreased levels of Families <italic>Clostridiaceae</italic>, <italic>Erysipelotrichaceae</italic>, and <italic>Lachnospiraceae</italic>, class <italic>Clostridiales</italic>, genera <italic>Coprococcus</italic>, <italic>Dorea</italic>, <italic>Lachnospira</italic>, <italic>Odoribacter</italic>, <italic>Ruminococcus</italic>, and <italic>Veillonella</italic>.</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B76">MacDonald et al., 2011</xref>
</td>
<td colspan="1" rowspan="1" valign="top">Phenylketonuria</td>
<td colspan="1" rowspan="1" valign="top">Human</td>
<td colspan="1" rowspan="1" valign="top">8-week open-label, single-arm, pilot intervention; Infants aged between 4 weeks and 6 months;<break></break>Formula Phe-free with prebiotic to replace a regular infant formula phe -free without prebiotics;<break></break>Measurement of Phe levels in blood;<break></break>Record of stool frequency, size, appearance, and consistency;<break></break>Stool samples analyzed for pH and bacterial groups (Fluorescence in situ hybridization technique).</td>
<td colspan="1" rowspan="1" valign="top">Influence of prebiotic scGOS/lcFOS addition to an infant Phe-free protein substitute</td>
<td colspan="1" rowspan="1" valign="top">Bifidobacteria and lactobacilli–enterococci levels were similar to those of healthy breast-fed infants and greater than those reported for infants on infant formula without prebiotics.</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B117">Sawin et al., 2015</xref>
</td>
<td colspan="1" rowspan="1" valign="top">Phenylketonuria</td>
<td colspan="1" rowspan="1" valign="top">Mice C57BL6/J PKU (Pah<sup>enu2</sup>)</td>
<td colspan="1" rowspan="1" valign="top">PKU (Pah<sup>enu2</sup>) and wild-type mice were fed with isoenergetic (Aminoacid, GMP, or casein) diets for 8 week;<break></break>Three experiments were done;<break></break>Measurement of SCFA by gas chromatography;<break></break>Quantification of plasma cytokines;<break></break>Analysis of splenocyte T cell populations by flow cytometry.</td>
<td colspan="1" rowspan="1" valign="top">Prebiotic effects of GMP</td>
<td colspan="1" rowspan="1" valign="top">Increased SCFAs levels;<break></break>Decreased levels of inflammatory cytokines<break></break>Decreased quantity of the Proteobacteria, genus <italic>Desulfovibrio</italic>.</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B39">Durrer et al., 2017</xref>
</td>
<td colspan="1" rowspan="1" valign="top">Phenylketonuria</td>
<td colspan="1" rowspan="1" valign="top">Mice C57BL6/J (PAH<sup>enu2</sup> mutant)</td>
<td colspan="1" rowspan="1" valign="top">
<italic>In vitro</italic> and <italic>in vivo</italic> test of a probiotic expressing the phenylalanine lyase gene;<break></break>Measurement of phe plasma pre and post-treatment;<break></break>Measurement of enzyme activity;<break></break>Prebiotic mixed into chow; Fecal culture and immunogenic evaluation.</td>
<td colspan="1" rowspan="1" valign="top">Assessment of a genetically engineered probiotic (GMO)</td>
<td colspan="1" rowspan="1" valign="top">Reduction of plasma Phe levels in the mouse model of PKU;<break></break>Survival of GMO Lactobacillus reuteri 100-23C in the mouse gastrointestinal tract, but no permanent colonization;<break></break>No immune response to transgenic protein.</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B46">Gertsman et al., 2015</xref>
</td>
<td colspan="1" rowspan="1" valign="top">Alkaptonuria Tyrosinemia</td>
<td colspan="1" rowspan="1" valign="top">Human</td>
<td colspan="1" rowspan="1" valign="top">Collection of samples from patients with alkaptonuria before and after treatment with NTBC plus samples of Tyrosinemia types I, I and transient patients;<break></break>Analysis of the sera y tQ-TOF LC/ MS metabolomic platform;<break></break>Untargeted metabolomics strategy;<break></break>
<italic>In vitro</italic> experiments with cultures of human cells and intestinal flora cultures to identify the nature of the link between 4-HPP and the elevated indoles.</td>
<td colspan="1" rowspan="1" valign="top">Evaluate the metabolic effects of nitisinone</td>
<td colspan="1" rowspan="1" valign="top">Increased levels of I3CHO, in patients treated with nitinisone.</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B43">Frye et al., 2016</xref>
</td>
<td colspan="1" rowspan="1" valign="top">Propionic acidemia (PA)</td>
<td colspan="1" rowspan="1" valign="top">Human lymphoblastoid cell lines (LCLs)</td>
<td colspan="1" rowspan="1" valign="top">Measurement of mitochondrial function in ASD and sex-age-matched control LCLs;<break></break>Incubation with PPA and reactive oxygen species.</td>
<td colspan="1" rowspan="1" valign="top">Effects of PPA in an unfavorable redox microenvironment</td>
<td colspan="1" rowspan="1" valign="top">PPA can have both beneficial and toxic effects on mitochondrial function, depending on concentration, exposure duration, and microenvironment redox state.</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B17">Buhnik-Rosenblau et al., 2012</xref>
</td>
<td colspan="1" rowspan="1" valign="top">Hemochromatosis type 1</td>
<td colspan="1" rowspan="1" valign="top">Mouse</td>
<td colspan="1" rowspan="1" valign="top">Comparison between wild-type and genetically deficient mouse;<break></break>Culture followed by tRFLP and 16S rRNA gene sequencing.</td>
<td colspan="1" rowspan="1" valign="top">Effects of iron metabolism (Irp2<sup>-/-</sup> and Hfe<sup>-/-</sup> genes) on microbiome</td>
<td colspan="1" rowspan="1" valign="top">Irp2<sup>-/-</sup>
<break></break>Increased levels of <italic>L. intestinalis</italic> compared to Hfe<sup>-/-</sup> mice and <italic>L. murinus</italic> compared to both Hfe<sup>-/-</sup>and WT mice;<break></break>Hfe<sup>-/-</sup>
<break></break>Increased levels of <italic>Enterococcus faecium</italic>;<break></break>Increased levels of <italic>L. johnsonii</italic> to both Hfe<sup>-/-</sup> and Irp2<sup>-/-</sup> mice compared to WT.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<attrib>PKU: phenylketonúria; Phe: phenylananine; Tyr: tyrosine; Trp: tryptophan; scGOS/lcFOS: neutral short chain galactooligosaccharides and long chain fructooligosaccharides; AA: aminoacids; GMP: glycromacropepide; SCFAs: short chain fatty Acids; GMO: genetically modified organism; I3CHO: indole-3-carboxaldehyde (exclusively produced by microbiota); PA: propionic academia; LCLs: Human lymphoblastoid cell lines; PPA: propionic acid; Irp2: iron regulatory protein 2 gene; Hfe: hemochromatosis protein gene. *The identified compounds are either exclusively synthesized or contributed by intestinal bacteria, as well as by human metabolism.</attrib>
</table-wrap-foot>
</table-wrap>
<fig id="f2" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<title>Common treatments used in IEM and its effects over the microbiome. Diet is an important modulator of the microbiome, and also is a very common treatment for several IEMs. Diets with restriction or abundance of certain nutrients can cause a dysbiotic state, leading to an abnormal immune signaling (inflammation), leaking of gut-blood barrier, and breaking of the energetic balance of cells, with potential to affect the whole body. Antibiotics, on other hand, cause rapid and significant drops in taxonomic richness, diversity and evenness. This can bring benefits, as in the case of propionic/methylmalonic acidemia patients, by decreasing the levels of propionic/methylmalonic acid, or not, as in the case of organ transplants, once patients treated with antibiotics during the perioperative period had an increased risk for graft <italic>vs.</italic> host disease. Organ transplantation is a treatment for several IEMs. Other drugs used for treating this class of genetic disease can also affect the microbiome or metabolite production, like nitinisone, used in treatment of tyrosinemia type I, that raises the levels of indoles which in turn have antineoplasic effects.</title>
</caption>
<graphic xlink:href="1415-4757-GMB-41-03-2017-0235-gf02"></graphic>
</fig>
<p>The majority of studies on microbiome–IEM interactions has focused on PKU. One of the most thorough among such studies compared the microbiome of eight patients with PKU to that of 10 healthy individuals by analysis of the 16S rRNA gene. In this study, <xref ref-type="bibr" rid="B104">Pinheiro de Oliveira <italic>et al.</italic> (2016)</xref> demonstrated reduced abundance of bacteria in the families Clostridiaceae, Erysipelotrichaceae, and Lachnospiraceae, class Clostridiales, and genera <italic>Coprococcus</italic>, <italic>Dorea</italic>, <italic>Lachnospira</italic>, <italic>Odoribacter</italic>, <italic>Ruminococcus,</italic> and <italic>Veillonella</italic> in patients with PKU, as well as an increase in <italic>Prevotella</italic>, <italic>Akkermansia</italic>, and Peptostreptococcaceae populations. Their metabolic prediction was associated both with starch and glucose metabolism and with AA metabolism (<xref ref-type="bibr" rid="B104">Pinheiro de Oliveira <italic>et al.</italic>, 2016</xref>). The authors raised the hypothesis that bacterial enrichment related to LPS biosynthesis, as observed in patients with PKU, might be associated with peripheral inflammation, as indicated by the proinflammatory circulating cytokine profile of these patients (<xref ref-type="bibr" rid="B26">Coakley <italic>et al.</italic>, 2014</xref>). In the same study, the authors found a correlation between microbiotic profile and circulating levels of phenylalanine (Phe), which might indicate a relationship between these patients’ microbiome, their treatment response, and their phenotype.</p>
<p>Focusing on the potential impacts of prebiotic treatment in individuals with PKU, a study reported by <xref ref-type="bibr" rid="B76">MacDonald <italic>et al.</italic> (2011)</xref> analyzed the effects of prebiotic oligosaccharides (scGOS/lcFOS) as an adjunct to the metabolic formula that forms the mainstay of PKU management. As breastfeeding is highly restricted in children with PKU, the authors theorized that a lack of the oligosaccharides present in breast milk might be associated with increased fecal pH and reduced bifidobacterial populations, thus predisposing the patient to infections. Administration of probiotics might mitigate this problem. The experiment assessed the dominant bacterial groups and found that the administered prebiotic oligosaccharides were able to maintain bifidobacteria levels and low fecal pH, without altering circulating levels of Phe. Despite the small sample size and lack of statistical power, these findings suggest that supplementing metabolic formula with prebiotics might be an interesting strategy in PKU, as the levels of Bifidobacteria and Lactobacilli–Enterococci at the end of the study were similar to those found in healthy children and higher than those reported in children who took the formula alone, without prebiotics. In the only patient who was previously receiving a diet without prebiotics, there was also a reduction in pathogens such as <italic>C. perfringens</italic> and <italic>C. difficile</italic> (group <italic>Clostridium histolyticum/lituseburense</italic>), <italic>E. coli, Shigella, Salmonella</italic>, and <italic>Klebsiella</italic> (subgroup Enterobacteriaceae) (<xref ref-type="bibr" rid="B76">MacDonald <italic>et al.</italic>, 2011</xref>).</p>
<p>Also regarding prebiotics, recent years have been promising in terms of the use of glycomacropeptide (GMP) as a substitute for Phe-free AA formula in patients with PKU. GMP is highly glycosylated and, when pure, constitutes a natural protein source that lacks the AAs (Phe, tyrosine (Tyr), tryptophan (Trp), histidine, cysteine, arginine) involved in some IEMs, including PKU (<xref ref-type="bibr" rid="B91">Neelima <italic>et al.</italic>, 2013</xref>). For now, human trials are seeking to ascertain the efficiency of GMP as a partial (50% formula, 50% GMP) or total replacement for the Phe-free AA formula. In trials, the use of GMP had no significant impact on circulating Phe levels and was preferred by patients over the formula, as GMP is more palatable and, according to patients, provides greater satiety than a formula-based diet alone (<xref ref-type="bibr" rid="B92">Ney <italic>et al.</italic>, 2016</xref>; <xref ref-type="bibr" rid="B150">Zaki <italic>et al.</italic>, 2016</xref>). This could make GMP an option to increase treatment adherence.</p>
<p>When the urine and plasma metabolome of the individuals with PKU were compared within the groups fed with AA-formula or GMP, differences were found between the metabolite profile linked to the microbes. There were no differences between fasting plasma concentrations of the Tyr and Trp, but individuals fed with AA formula had a 50% higher intake of Tyr and Trp. This can be explained as a result of higher degradation by the intestinal microbes, raising the levels of microbiome-derived compounds from Tyr. Some of these compounds are potentially harmful. There was no differential degradation of Trp, but the metabolism of Trp via the kynurenine pathway was evidenced by higher levels of metabolites linked to this pathway and might be linked with inflammation patterns. Change in plasma profile of secondary bile acids, but not primary bile acids, supports the statement that there are alterations in the gut microbiome with ingestion of AA-formula and GMP, and reinforces the prebiotic proprieties of the GMP (<xref ref-type="bibr" rid="B93">Ney <italic>et al.</italic>, 2017</xref>).</p>
<p>Although the effect of GMP on the human gut microbiome has yet to be studied, in mice, GMP was associated with control of Th2-type immune responses, increased <italic>Lactobacillus</italic> and <italic>Bifidobacterium</italic> populations in as little as three days after treatment (<xref ref-type="bibr" rid="B60">Jiménez <italic>et al.</italic>, 2016</xref>), elevated levels of SCFAs and reduced levels of proinflammatory cytokines, and reduced Proteobacteria counts (genus <italic>Desulfovibrio</italic>) without affecting circulating Phe levels (<xref ref-type="bibr" rid="B117">Sawin <italic>et al.</italic>, 2015</xref>). The genus <italic>Desulfovibrio</italic> is associated with production of hydrogen sulfate, a cytotoxic compound found at higher levels in patients with ulcerative colitis (<xref ref-type="bibr" rid="B111">Rowan <italic>et al.</italic>, 2010</xref>).</p>
<p>Regarding disorders of tyrosine metabolism, <xref ref-type="bibr" rid="B46">Gertsman <italic>et al.</italic> (2015)</xref> described the metabolic effect of nitisinone (NTBC or 2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) in patients with alkaptonuria. Analysis of their metabolic profile showed that indole levels were increased in treated patients as compared with controls. Indoles play a key role in signaling pathways (as building blocks for melanin and serotonin) and intercellular communication, facilitate quorum sensing, and have been uniquely associated with dietary intake and microbial metabolism of tryptophan. Among the indoles found to be increased, indole-3-carboxaldehyde (I3CHO) is produced exclusively by the microbiota, while the other two are produced by human cells (<xref ref-type="bibr" rid="B46">Gertsman <italic>et al.</italic>, 2015</xref>). The authors stressed that the reduced form of I3CHO, indole-3-carbinol, a compound also found in cruciferous vegetables, is associated with the prevention of several neoplasms.</p>
<p>Animal experiments also suggest that genetic defects in the host may alter the composition of the gut microbiota, leading to dysbiosis due to a buildup of substances in the cells or lumen of the bowel (<xref ref-type="bibr" rid="B17">Buhnik-Rosenblau <italic>et al.</italic>, 2012</xref>). This effect has been observed in hemochromatosis. Hemochromatosis is a disease caused by excess iron absorption by gut cells, which leads to iron overload. This usually becomes clinically detectable in adulthood and is damaging to many organs, including the liver, pancreas (causing diabetes), heart, and skin (<xref ref-type="bibr" rid="B4">Babitt and Lin, 2011</xref>). Mutations in the <italic>HFE</italic> gene account for the majority of cases of hereditary hemochromatosis, especially in individuals of Northern European descent (<xref ref-type="bibr" rid="B7">Barton, 2013</xref>). In a study of mice with mutations in two genes that encode proteins involved in regulation of iron homeostasis (<italic>HFE</italic>
<sup><italic>-/-</italic></sup>and <italic>Irp2</italic>
<sup>-/-</sup>), <xref ref-type="bibr" rid="B17">Buhnik-Rosenblau <italic>et al.</italic> (2012)</xref> found abnormalities particularly in resident populations of lactic-acid bacteria, both in <italic>Irp2-</italic>mutant and in <italic>HFE</italic>-mutant mice as compared to controls.</p>
<p>The gut microbiome produces several metabolites, including PPA, a SCFA implicated in several diseases. In autistic populations, the level of the phylum <italic>Firmicutes</italic> is increased and was largely attributable to <italic>Clostridia</italic> class with <italic>Ruminococcaceae</italic> and <italic>Lachnospiraceae</italic> families. The differences in Clostridia species in children with autism spectrum disorder include greater abundance of <italic>Clostridium</italic> clusters I, II, XI and <italic>C. bolteae</italic> (<xref ref-type="bibr" rid="B42">Finegold <italic>et al.</italic>, 2002</xref>; <xref ref-type="bibr" rid="B128">Song <italic>et al.</italic>, 2004</xref>; <xref ref-type="bibr" rid="B100">Parracho <italic>et al.</italic>, 2005</xref>; <xref ref-type="bibr" rid="B144">Williams <italic>et al.</italic>, 2011</xref>; <xref ref-type="bibr" rid="B134">Strati <italic>et al.</italic>, 2017</xref>). Several <italic>Ruminococcaceae</italic> and <italic>Lachnospiraceae</italic> are known butyrate producers and may thus influence SCFA levels (<xref ref-type="bibr" rid="B75">Louis <italic>et al.</italic>, 2010</xref>). So, the treatment with antibiotics can affect producers of SCFA. Some patients’ symptoms improve transiently when antibiotics are administered (<xref ref-type="bibr" rid="B115">Sandler <italic>et al.</italic>, 2000</xref>; <xref ref-type="bibr" rid="B124">Shaw 2010</xref>). Curiously, a similar effect is seen in patients with propionic acidemia, who can experience the same neurodevelopmental complications seen in autism (<xref ref-type="bibr" rid="B145">Witters <italic>et al.</italic>, 2016</xref>). Among the various roles played by PPA, it was recently reported to act as a modulator of mitochondrial function. In a study of autism and control cell lines, the effects of PPA depended not only on the concentration of the acid, but also on the level of reactive oxygen species (ROS) present, as ROS influence mitochondrial ability to use PPA as an energy source. Thus, PPA could have beneficial effects in individuals without mitochondrial dysfunction, and harmful effects in individuals with an unfavorable metabolic status and elevated levels of ROS (<xref ref-type="bibr" rid="B43">Frye <italic>et al.</italic>, 2016</xref>). In methylmalonic acidemia, which shares several symptoms and management strategies with propionic acidemia, vitamin B<sub>12</sub> (cobalamin) is also used as treatment in responsive patients, in addition to antibiotics. This vitamin is synthesized by some gut bacteria, and is also a regulator of microbiome composition and function (<xref ref-type="bibr" rid="B8">Baumgartner <italic>et al.</italic>, 2014</xref>; <xref ref-type="bibr" rid="B36">Degnan <italic>et al.</italic>, 2014</xref>).</p>
<p>The microbiome can also be considered an exogenous source of tetrahydrobiopterin (BH<sub>4</sub>), another important metabolite of gut bacteria. BH<sub>4</sub> is a key cofactor for several regulatory enzymes, as Phenylalanine-4-hydroxylase, which catalyzes the conversion of L-phenylalanine to L-tyrosine. The BH<sub>4</sub> has also been shown to improve working memory and cerebral activation (<xref ref-type="bibr" rid="B24">Christ <italic>et al.</italic>, 2013</xref>). In rodents, BH<sub>4</sub> production is age-dependent and is related to the presence of Actinobacteria in the bowel, especially <italic>Adlercreutzia equolifaciens</italic> and <italic>Microbacterium schleiferi</italic>. These same species have been identified in the human gut microbiome (<xref ref-type="bibr" rid="B9">Belik <italic>et al.</italic>, 2017</xref>). Very little is known about the determinants of responsiveness to BH<sub>4</sub> therapy and its effects on cerebral activity and cognition, but these effects are known to be multifactorial, as they vary across individuals with the same genotype (<xref ref-type="bibr" rid="B101">Pérez <italic>et al.</italic>, 2005</xref>). The discovery that BH<sub>4</sub> is naturally produced by gut microbiota has implications for translational medicine, as this cofactor is used in the treatment of some patients with PKU.</p>
<p>The long-term perspective is that elucidation of the metabolic role of the microbiota and identification of which species play these roles will pave the way for manipulating the microbiome, so that pathways beneficial to the host are stimulated, while those harmful to the host are inhibited. In this line, some authors have raised the hypothesis of using methanogenic bacteria normally present in the human bowel to control metabolites such as trimethylamine (TMA), bypassing the normal route of trimethylamine N-oxide (TMAO) production as an intermediate for CH<sub>4</sub> to an alternative pathway (<xref ref-type="bibr" rid="B15">Brugère <italic>et al.</italic>, 2014</xref>). In the liver, deficiency in the pathway of TMA conversion into TMAO leads to trimethylaminuria, an IEM that causes strong body odor, impairing the patients’ quality of life and interpersonal relations (<xref ref-type="bibr" rid="B77">Mackay <italic>et al.</italic>, 2011</xref>). Diets rich in compounds such as phosphatidylcholine, choline, betaine, and L-carnitine generate TMA via the gut microbiota, which is then converted in TMAO by the liver. High levels of TMAO are associated with increased risk of cardiovascular disease in the general population (<xref ref-type="bibr" rid="B142">Wang <italic>et al.</italic>, 2011</xref>; <xref ref-type="bibr" rid="B63">Koeth <italic>et al.</italic>, 2013</xref>; <xref ref-type="bibr" rid="B49">Gregory <italic>et al.</italic>, 2015</xref>; <xref ref-type="bibr" rid="B71">Liu <italic>et al.</italic>, 2015b</xref>). Making the transition from theory into practice, administration of the probiotic <italic>Lactobacillus reuteri,</italic> engineered to express a phenylalanine lyase gene from the cyanobacteria <italic>Anabaena variabilis</italic>, successfully treated mice with PKU. Blood levels of Phe declined after the fourth day of treatment and remained low throughout the experiment, with no permanent colonization of the gut (<xref ref-type="bibr" rid="B39">Durrer <italic>et al.</italic>, 2017</xref>), suggesting potential for modified probiotics in the treatment of IEMs.</p>
<p>The creation of genetically modified probiotics design especially to normalize defective metabolic pathways in the host is only one of the many potential advantages of microbiome research. IEMs are characterized by substantial variability in presentation, and genotype alone cannot explain patients’ clinical pictures. The microbiome may contribute significantly to factors such as tolerance to certain nutrients and responsiveness to cofactors (and to treatment itself). Studying the microbiomes of patients with IEMs may provide valuable tools for clinical practice, both advancing our understanding of phenotypes and facilitating the development of new biomarkers and therapies.</p>
</sec>
<sec>
<title>Main questions about microbioma and IEM and how to address them</title>
<p>There are some important issues involved in the study of the human microbiome in IEM. First of all, most of the diseases that compound the IEM class are rare, and usually there are subclasses within the same IEM. This is the reason why the studies normally have a small number of participants. Second, the microbiome is mainly influenced by diet, and diet overload or restriction is one of most common treatments for IEM. This is one of reasons that make obtaining an adequate control group very difficult. Third, this class of diseases is derived of a metabolic genetic defect, and defects in a metabolic gene also affect the microbiome. So, if a dysbiotic state is observed in this group of patients will it reflect the genetic or the diet effect? Taken together, all the facts above make it very hard to obtain a homogeneous and statistically valid group of untreated patients and make difficult the comparison pre and post-treatment to verify if the altered microbiome is mainly affected by genetic or diet effects. Additional difficulty is added by the fact that several metabolic diseases, if untreated, can lead to severe impacts through life, so IEM patients should start to be treated as soon as possible.</p>
<p>Despite the difficulties, studying the patterns of the microbiome in groups of treated patients offers the possibility to evaluate the real impact of the genetic defect and diet on the microbiome. Patients need lifelong treatment, and the intragroup study of phenotype, microbiome and diet can be elucidative for some ancient questions that remain unknown. PKU patients, for instance, were studied in light of the microbiome by Pinheiro <xref ref-type="bibr" rid="B104">de Oliveira <italic>et al.</italic> (2016)</xref> (see <xref ref-type="table" rid="t2">Table 2</xref>). Even though not capable of answering the question if alteration comes from diet or genetics, a microbiome alteration correlated with Phe blood levels was observed. This is exciting data, due to the fact that it can help explain why some patients are more tolerant to Phe than others, despite having the same genotypes.</p>
<p>In an IEM, the genetic defect and the diet factors coexist, so the measure of macro- and micronutrients ingested is required. Diet has a strong impact on the microbiome, and in spite of patients having similar lines of treatment all over the world, the source of fibers, carbohydrates and proteins can vary geographically and/or culturally. For this reason, microbiome studies should not combine patients of geographically distinct regions or culture to raise the number of participants. Rather, these studies must be done locally and then, if methodologically possible, make comparisons that take into account the dietetic/cultural/geographic factors.</p>
<p>As detailed above, there are several other factors that can influence and be influenced by the microbiome. Important data as sex, age, body mass index, type of birth delivery, breast feeding (duration and transition to solid food), antibiotic and other drug usage, vitamin supplementation, as well as physical exercise, and other diseases (physical and/or mental) must be collected and also analyzed. All subjects included in studies that aim to characterize the microbiome of certain IEMs should be three years or older to avoid the period of drastic changes in microbiome composition due to the typical change in diet during this period. Given that the microbiome varies according to the stage of life and sex, and certain cultures can also exert some influence, the best way to avoid interference of age and sex is the sex-age-matched strategy.</p>
<p>Another useful strategy is based on experimental studies using animal models. This strategy is very important since animal models have less genetic variation and are maintained in a highly controlled environment (that includes diet and/or a germ-free environment). Also, a high the number of subjects can be easily obtained in such research. This is the better model for initial tests of genetically engineered probiotics and correlations with diseases caused by the genetic defect in the absence or presence of the treatment. This kind of study, besides not being capable of fully reproducing the human reality, can work to generate hypotheses and help to provide better strategies and comprehension of studies done in humans.</p>
<p>With the development of NGS tools, procedures are no longer the main limitation for human microbiome studies. Microbiome data is currently obtained by three different approaches: 1) by 16S rRNA gene partial sequencing, 2) by whole DNA shotgun metagenomic sequencing, or 3) by metatranscriptomics (mRNA-seq), to access the active gene expression pattern For instance, the 16S rRNA gene sequencing method is largely used and has been the first choice method among researchers. Reasons for choosing this approach include the availability of a comprehensive database and scalability. Moreover, studies based in metatranscriptomics require a better control for sample collection to RNA/metabolites processing. Metagenomics, metatranscriptomics and all other “omics”, and the associated bioinformatics techniques are allowing comparative analyses in an unprecedented way. All of these tools allow for testing a recent hypothesis related to the presence of a common set of microbial taxa universally present in healthy individuals (<xref ref-type="bibr" rid="B140">Turnbaugh <italic>et al.</italic>, 2007</xref>), also known as microbial core. However large variations in the taxonomic composition observed in the human microbiome rapidly refute such a hypothesis (<xref ref-type="bibr" rid="B5">Bäckhed <italic>et al.</italic>, 2012</xref>). Due to the well-known microbial functional redundancy in nature, an alternative hypothesis is the presence of a functional core represented by a set of metabolic functions that are performed by the microbiome within a particular habitat, but are not necessarily provided by the same organisms in different people (<xref ref-type="bibr" rid="B121">Shafquat <italic>et al.</italic>, 2014</xref>). Still, studies devoted to better understand how deeply the microbiome can affect an organism with critical metabolic pathways that are naturally altered, are just in the early stages. Multidisciplinary efforts need to be done to aggregate modern techniques of sequencing and identification of metabolites that can lead to the phenotype or drug effect in question. Microbial sequencing alone will not be capable of explaining the phenotype, but is a fundamental tool in the understanding of the process. Additional techniques based on metabolomics analysis and RNA-seq, as well as gathering information about the immune system and SCFA levels can offer fundamental pieces of information in the process.</p>
</sec>
<sec sec-type="conclusions">
<title>Conclusions</title>
<p>Studies on the microbiome in IEMs are scarce. The effects of the genetic defect itself and of treatment in IEMs, especially in the long term, have yet to be fully understood. As IEMs are commonly managed through dietary intervention (nutrient overload and/or restriction), dysbiosis is a possibility. This dysbiotic status would alter the patients’ already compromised metabolic state even further, inducing or worsening abnormalities in secondary metabolic pathways, and thus contributing to phenotypic manifestations, especially liver and brain involvement. Dysbiosis can be treated with antibiotic therapy, dietary prebiotics, or fecal transplant, alone or in combination. The administration of probiotics engineered to at least partly meet the metabolic needs of the IEM-affected host has practically unexplored therapeutic potential and may constitute an intervention that is simple to administer, yet has a major impact on the patients’ lives. Collectively, microbiome research in patients with IEMs can not only contribute significantly to our understanding of the pathophysiology of these diseases and to the development of new biomarkers and therapies, but also help to improve the long-term quality of life in affected patients.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The authors acknowledge the financial support of CAPES, FAPERGS and FIPE-HCPA.</p>
</ack>
<fn-group>
<fn fn-type="other" id="fn1">
<p>
<italic>Associate Editor: Maria Rita Passos-Bueno</italic>
</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alfadhel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Benmeakel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hossain</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Al Mutairi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Al Othaim</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Alfares</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Al Balwi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Alzaben</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Eyaid</surname>
<given-names>W</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>Thirteen year retrospective review of the spectrum of inborn errors of metabolism presenting in a tertiary center in Saudi Arabia</article-title>
<source/>Orphanet J Rare Dis
          <volume>11</volume>
<fpage>126</fpage>
<pub-id pub-id-type="pmid">27629047</pub-id>
</element-citation>
</ref>
<ref id="B2">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Argmann</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Houten</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schadt</surname>
<given-names>EE</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>A next generation multiscale view of inborn errors of metabolism</article-title>
<source/>Cell Metab
          <volume>23</volume>
<fpage>13</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="pmid">26712461</pub-id>
</element-citation>
</ref>
<ref id="B3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashton</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Colquhoun</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Cleary</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Coelho</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Haggarty</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mulder</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Batra</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Afzal</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Beattie</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>KP</given-names>
</name>
<etal></etal>
</person-group>
<year>2017</year>
<article-title>16S sequencing and functional analysis of the fecal microbiome during treatment of newly diagnosed pediatric inflammatory bowel disease</article-title>
<source/>Medicine (Baltimore)
          <volume>96</volume>
<fpage>e7347</fpage>
<pub-id pub-id-type="pmid">28658154</pub-id>
</element-citation>
</ref>
<ref id="B4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Babitt</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>HY</given-names>
</name>
</person-group>
<year>2011</year>
<article-title>The molecular pathogenesis of hereditary hemochromatosis</article-title>
<source/>Semin Liver Dis
          <volume>31</volume>
<fpage>280</fpage>
<lpage>292</lpage>
<pub-id pub-id-type="pmid">21901658</pub-id>
</element-citation>
</ref>
<ref id="B5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bäckhed</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Fraser</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Ringel</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sanders</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Sartor</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Sherman</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Versalovic</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Finlay</surname>
<given-names>BB</given-names>
</name>
</person-group>
<year>2012</year>
<article-title>Defining a healthy human gut microbiome: Current concepts, future directions, and clinical applications</article-title>
<source/>Cell Host Microbe
          <volume>12</volume>
<fpage>611</fpage>
<lpage>622</lpage>
<pub-id pub-id-type="pmid">23159051</pub-id>
</element-citation>
</ref>
<ref id="B6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balmer</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Slack</surname>
<given-names>E</given-names>
</name>
<name>
<surname>de Gottardi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lawson</surname>
<given-names>MAE</given-names>
</name>
<name>
<surname>Hapfelmeier</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Miele</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Grieco</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Van Vlierberghe</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fahrner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Patuto</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<year>2014</year>
<article-title>The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota</article-title>
<source/>Sci Transl Med
          <volume>6</volume>
<fpage>237ra66</fpage>
</element-citation>
</ref>
<ref id="B7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barton</surname>
<given-names>JC</given-names>
</name>
</person-group>
<year>2013</year>
<article-title>Hemochromatosis and iron overload: From bench to clinic</article-title>
<source/>Am J Med Sci
          <volume>346</volume>
<fpage>403</fpage>
<lpage>412</lpage>
<pub-id pub-id-type="pmid">24157962</pub-id>
</element-citation>
</ref>
<ref id="B8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baumgartner</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Hörster</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dionisi-Vici</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Haliloglu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Karall</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Chapman</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Huemer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hochuli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Assoun</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ballhausen</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<year>2014</year>
<article-title>Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia</article-title>
<source/>Orphanet J Rare Dis
          <volume>9</volume>
<fpage>130</fpage>
<pub-id pub-id-type="pmid">25205257</pub-id>
</element-citation>
</ref>
<ref id="B9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belik</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shifrin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Arning</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bottiglieri</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Daigneault</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Allen-Vercoe</surname>
<given-names>E</given-names>
</name>
</person-group>
<year>2017</year>
<article-title>Intestinal microbiota as a tetrahydrobiopterin exogenous source in <italic>hph-1</italic> mice</article-title>
<source/>Sci Rep
          <volume>7</volume>
<fpage>39854</fpage>
<pub-id pub-id-type="pmid">28079055</pub-id>
</element-citation>
</ref>
<ref id="B10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bilder</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Kobori</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Cohen-Pfeffer</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Jurecki</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>ML</given-names>
</name>
</person-group>
<year>2017</year>
<article-title>Neuropsychiatric comorbidities in adults with phenylketonuria: A retrospective cohort study</article-title>
<source/>Mol Genet Metab
          <volume>121</volume>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">28285739</pub-id>
</element-citation>
</ref>
<ref id="B11">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boelens</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Orchard</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Wynn</surname>
<given-names>RF</given-names>
</name>
</person-group>
<year>2014</year>
<article-title>Transplantation in inborn errors of metabolism: current considerations and future perspectives</article-title>
<source/>Br J Haematol
          <volume>167</volume>
<fpage>293</fpage>
<lpage>303</lpage>
<pub-id pub-id-type="pmid">25074667</pub-id>
</element-citation>
</ref>
<ref id="B12">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonini</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>DF</given-names>
</name>
</person-group>
<year>1997</year>
<article-title>Molecular cloning and tissue expression of a novel orphan G protein-coupled receptor from rat lung</article-title>
<source/>Biochem Biophys Res Commun
          <volume>234</volume>
<fpage>190</fpage>
<lpage>193</lpage>
<pub-id pub-id-type="pmid">9168987</pub-id>
</element-citation>
</ref>
<ref id="B13">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boyer</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Barclay</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Burrage</surname>
<given-names>LC</given-names>
</name>
</person-group>
<year>2015</year>
<article-title>Inherited metabolic disorders: Aspects of chronic nutrition management</article-title>
<source/>Nutr Clin Pract Off Publ Am Soc Parenter Enter Nutr
          <volume>30</volume>
<fpage>502</fpage>
<lpage>510</lpage>
</element-citation>
</ref>
<ref id="B14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braniste</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Al-Asmakh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kowal</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Anuar</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Abbaspour</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tóth</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Korecka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bakocevic</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>NL</given-names>
</name>
<etal></etal>
</person-group>
<year>2014</year>
<article-title>The gut microbiota influences blood-brain barrier permeability in mice</article-title>
<source/>Sci Transl Med
          <volume>6</volume>
<fpage>263ra158</fpage>
</element-citation>
</ref>
<ref id="B15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brugère</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Borrel</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gaci</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tottey</surname>
<given-names>W</given-names>
</name>
<name>
<surname>O’Toole</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Malpuech-Brugère</surname>
<given-names>C</given-names>
</name>
</person-group>
<year>2014</year>
<article-title>Archaebiotics: Proposed therapeutic use of archaea to prevent trimethylaminuria and cardiovascular disease</article-title>
<source/>Gut Microbes
          <volume>5</volume>
<fpage>5</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="pmid">24247281</pub-id>
</element-citation>
</ref>
<ref id="B16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brunetti-Pierri</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>B</given-names>
</name>
</person-group>
<year>2005</year>
<article-title>Gene therapy for inborn errors of liver metabolism</article-title>
<source/>Mol Genet Metab
          <volume>86</volume>
<fpage>13</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="pmid">16154372</pub-id>
</element-citation>
</ref>
<ref id="B17">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buhnik-Rosenblau</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Moshe-Belizowski</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Danin-Poleg</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Meyron-Holtz</surname>
<given-names>EG</given-names>
</name>
</person-group>
<year>2012</year>
<article-title>Genetic modification of iron metabolism in mice affects the gut microbiota</article-title>
<source/>Biometals Int J Role Met Ions Biol Biochem Med
          <volume>25</volume>
<fpage>883</fpage>
<lpage>892</lpage>
</element-citation>
</ref>
<ref id="B18">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cani</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Possemiers</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Van de Wiele</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Guiot</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Everard</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rottier</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Geurts</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Naslain</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Neyrinck</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>DM</given-names>
</name>
<etal></etal>
</person-group>
<year>2009</year>
<article-title>Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability</article-title>
<source/>Gut
          <volume>58</volume>
<fpage>1091</fpage>
<lpage>1103</lpage>
<pub-id pub-id-type="pmid">19240062</pub-id>
</element-citation>
</ref>
<ref id="B19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chassaing</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Koren</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Goodrich</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Poole</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Srinivasan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ley</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Gewirtz</surname>
<given-names>AT</given-names>
</name>
</person-group>
<year>2015</year>
<article-title>Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome</article-title>
<source/>Nature
          <volume>519</volume>
<fpage>92</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="pmid">25731162</pub-id>
</element-citation>
</ref>
<ref id="B20">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chevalier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Stojanovic</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Colin</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Suarez-Zamorano</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tarallo</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Veyrat-Durebex</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rigo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fabbiano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stevanovic</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hagemann</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<year>2015</year>
<article-title>Gut Microbiota Orchestrates Energy Homeostasis during Cold</article-title>
<source/>Cell
          <volume>163</volume>
<fpage>1360</fpage>
<lpage>1374</lpage>
<pub-id pub-id-type="pmid">26638070</pub-id>
</element-citation>
</ref>
<ref id="B21">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chinsky</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ficicioglu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>van Karnebeek</surname>
<given-names>CDM</given-names>
</name>
<name>
<surname>Grompe</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Waisbren</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Gucsavas-Calikoglu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wasserstein</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Coakley</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<year>2017</year>
<article-title>Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations</article-title>
<source/>Genet Med
          <volume>19</volume>
<fpage>1380</fpage>
</element-citation>
</ref>
<ref id="B22">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiu</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Heesters</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Ghasemlou</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Von Hehn</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Tran</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wainger</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Strominger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Muralidharan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Horswill</surname>
<given-names>AR</given-names>
</name>
<etal></etal>
</person-group>
<year>2013</year>
<article-title>Bacteria activate sensory neurons that modulate pain and inflammation</article-title>
<source/>Nature
          <volume>501</volume>
<fpage>52</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="pmid">23965627</pub-id>
</element-citation>
</ref>
<ref id="B23">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Blaser</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<year>2012</year>
<article-title>The Human Microbiome: at the interface of health and disease</article-title>
<source/>Nat Rev Genet
          <volume>13</volume>
<fpage>260</fpage>
<lpage>270</lpage>
<pub-id pub-id-type="pmid">22411464</pub-id>
</element-citation>
</ref>
<ref id="B24">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christ</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Moffitt</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Peck</surname>
<given-names>D</given-names>
</name>
<name>
<surname>White</surname>
<given-names>DA</given-names>
</name>
</person-group>
<year>2013</year>
<article-title>The effects of tetrahydrobiopterin (BH4) treatment on brain function in individuals with phenylketonuria</article-title>
<source/>NeuroImage Clin
          <volume>3</volume>
<fpage>539</fpage>
<lpage>547</lpage>
<pub-id pub-id-type="pmid">24371792</pub-id>
</element-citation>
</ref>
<ref id="B25">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Pamp</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Surana</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Edelman</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Troy</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Reading</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Villablanca</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mora</surname>
<given-names>JR</given-names>
</name>
<etal></etal>
</person-group>
<year>2012</year>
<article-title>Gut immune maturation depends on colonization with a host-specific microbiota</article-title>
<source/>Cell
          <volume>149</volume>
<fpage>1578</fpage>
<lpage>1593</lpage>
<pub-id pub-id-type="pmid">22726443</pub-id>
</element-citation>
</ref>
<ref id="B26">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coakley</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Douglas</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>R</given-names>
</name>
</person-group>
<year>2014</year>
<article-title>Phenylketonuria is a condition of inflammation associated with high BMI and low bone turnover (1034.2)</article-title>
<source/>FASEB J
          <volume>28</volume>
<fpage>1034.2</fpage>
</element-citation>
</ref>
<ref id="B27">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coleman</surname>
<given-names>OI</given-names>
</name>
<name>
<surname>Nunes</surname>
<given-names>T</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>Role of the microbiota in colorectal cancer: Updates on microbial associations and therapeutic implications</article-title>
<source/>BioResearch Open Access
          <volume>5</volume>
<fpage>279</fpage>
<lpage>288</lpage>
<pub-id pub-id-type="pmid">27790385</pub-id>
</element-citation>
</ref>
<ref id="B28">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cotillard</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Prifti</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pons</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Le Chatelier</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Almeida</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Quinquis</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Levenez</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Galleron</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<year>2013</year>
<article-title>Dietary intervention impact on gut microbial gene richness</article-title>
<source/>Nature
          <volume>500</volume>
<fpage>585</fpage>
<lpage>588</lpage>
<pub-id pub-id-type="pmid">23985875</pub-id>
</element-citation>
</ref>
<ref id="B29">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crenn</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Maillot</surname>
<given-names>F</given-names>
</name>
</person-group>
<year>2007</year>
<article-title>Principes et contraintes des régimes au cours des maladies neurométaboliques chez l’adulte</article-title>
<source/>Rev Neurol (Paris)
          <volume>163</volume>
<fpage>936</fpage>
<lpage>941</lpage>
<pub-id pub-id-type="pmid">18033030</pub-id>
</element-citation>
</ref>
<ref id="B30">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cummings</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Pomare</surname>
<given-names>EW</given-names>
</name>
<name>
<surname>Branch</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Naylor</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Macfarlane</surname>
<given-names>GT</given-names>
</name>
</person-group>
<year>1987</year>
<article-title>Short chain fatty acids in human large intestine, portal, hepatic and venous blood</article-title>
<source/>Gut
          <volume>28</volume>
<fpage>1221</fpage>
<lpage>1227</lpage>
<pub-id pub-id-type="pmid">3678950</pub-id>
</element-citation>
</ref>
<ref id="B31">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dabrowska</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Witkiewicz</surname>
<given-names>W</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>Correlations of host genetics and gut microbiome composition</article-title>
<source/>Front Microbiol
          <volume>2016</volume>
<fpage>1357</fpage>
</element-citation>
</ref>
<ref id="B32">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Das</surname>
<given-names>AM</given-names>
</name>
</person-group>
<year>2017</year>
<article-title>Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)</article-title>
<source/>Appl Clin Genet
          <volume>10</volume>
<fpage>43</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="pmid">28769581</pub-id>
</element-citation>
</ref>
<ref id="B33">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>David</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Maurice</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Carmody</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Gootenberg</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Button</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Wolfe</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Devlin</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Varma</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Fischbach</surname>
<given-names>MA</given-names>
</name>
<etal></etal>
</person-group>
<year>2014</year>
<article-title>Diet rapidly and reproducibly alters the human gut microbiome</article-title>
<source/>Nature
          <volume>505</volume>
<fpage>559</fpage>
<lpage>563</lpage>
<pub-id pub-id-type="pmid">24336217</pub-id>
</element-citation>
</ref>
<ref id="B34">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Angelis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Francavilla</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Piccolo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>De Giacomo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gobbetti</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2015</year>
<article-title>Autism spectrum disorders and intestinal microbiota</article-title>
<source/>Gut Microbes
          <volume>6</volume>
<fpage>207</fpage>
<lpage>213</lpage>
<pub-id pub-id-type="pmid">25835343</pub-id>
</element-citation>
</ref>
<ref id="B35">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Filippo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cavalieri</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Di Paola</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ramazzotti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Poullet</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Massart</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Collini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pieraccini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lionetti</surname>
<given-names>P</given-names>
</name>
</person-group>
<year>2010</year>
<article-title>Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa</article-title>
<source/>Proc Natl Acad Sci U S A
          <volume>107</volume>
<fpage>14691</fpage>
<lpage>14696</lpage>
<pub-id pub-id-type="pmid">20679230</pub-id>
</element-citation>
</ref>
<ref id="B36">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Degnan</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Taga</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>AL</given-names>
</name>
</person-group>
<year>2014</year>
<article-title>Vitamin B12 as a modulator of gut microbial ecology</article-title>
<source/>Cell Metab
          <volume>20</volume>
<fpage>769</fpage>
<lpage>778</lpage>
<pub-id pub-id-type="pmid">25440056</pub-id>
</element-citation>
</ref>
<ref id="B37">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Desbonnet</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Traplin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>O’Sullivan</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Crispie</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Moloney</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Cotter</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Dinan</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>JF</given-names>
</name>
</person-group>
<year>2015</year>
<article-title>Gut microbiota depletion from early adolescence in mice: Implications for brain and behaviour</article-title>
<source/>Brain Behav Immun
          <volume>48</volume>
<fpage>165</fpage>
<lpage>173</lpage>
<pub-id pub-id-type="pmid">25866195</pub-id>
</element-citation>
</ref>
<ref id="B38">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donaldson</surname>
<given-names>GP</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Mazmanian</surname>
<given-names>SK</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>Gut biogeography of the bacterial microbiota</article-title>
<source/>Nat Rev Microbiol
          <volume>14</volume>
<fpage>20</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">26499895</pub-id>
</element-citation>
</ref>
<ref id="B39">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durrer</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Hunt von Herbing</surname>
<given-names>I</given-names>
</name>
</person-group>
<year>2017</year>
<article-title>Genetically engineered probiotic for the treatment of phenylketonuria (PKU); assessment of a novel treatment in vitro and in the PAHenu2 mouse model of PKU</article-title>
<source/>PLoS One
          <volume>12</volume>
<fpage>e0176286</fpage>
<pub-id pub-id-type="pmid">28520731</pub-id>
</element-citation>
</ref>
<ref id="B40">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Etienne-Mesmin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Vijay-Kumar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gewirtz</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Chassaing</surname>
<given-names>B</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>Hepatocyte Toll-like Receptor 5 promotes bacterial clearance and protects mice against high-fat diet-induced liver disease</article-title>
<source/>Cell Mol Gastroenterol Hepatol
          <volume>2</volume>
<fpage>584</fpage>
<lpage>604</lpage>
<pub-id pub-id-type="pmid">28090564</pub-id>
</element-citation>
</ref>
<ref id="B41">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ezgu</surname>
<given-names>F</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>Inborn Errors of Metabolism</article-title>
<source/>Adv Clin Chem
          <volume>73</volume>
<fpage>195</fpage>
<lpage>250</lpage>
<pub-id pub-id-type="pmid">26975974</pub-id>
</element-citation>
</ref>
<ref id="B42">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finegold</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Molitoris</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vaisanen</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Bolte</surname>
<given-names>E</given-names>
</name>
<name>
<surname>McTeague</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sandler</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wexler</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Marlowe</surname>
<given-names>EM</given-names>
</name>
<etal></etal>
</person-group>
<year>2002</year>
<article-title>Gastrointestinal microflora studies in late-onset autism</article-title>
<source/>Clin Infect Dis
          <volume>35</volume>
<fpage>S6</fpage>
<lpage>S16</lpage>
<pub-id pub-id-type="pmid">12173102</pub-id>
</element-citation>
</ref>
<ref id="B43">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chacko</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wynne</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bennuri</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Slattery</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Tippett</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Delhey</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Melnyk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kahler</surname>
<given-names>SG</given-names>
</name>
<etal></etal>
</person-group>
<year>2016</year>
<article-title>Modulation of mitochondrial function by the microbiome metabolite propionic acid in autism and control cell lines</article-title>
<source/>Transl Psychiatry
          <volume>6</volume>
<fpage>e927</fpage>
<pub-id pub-id-type="pmid">27779624</pub-id>
</element-citation>
</ref>
<ref id="B44">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bonder</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Cenit</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Tigchelaar</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Maatman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dekens</surname>
<given-names>JAM</given-names>
</name>
<name>
<surname>Brandsma</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Marczynska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Imhann</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Weersma</surname>
<given-names>RK</given-names>
</name>
<etal></etal>
</person-group>
<year>2015</year>
<article-title>The gut microbiome contributes to a substantial proportion of the variation in blood lipids</article-title>
<source/>Circ Res
          <volume>117</volume>
<fpage>817</fpage>
<lpage>824</lpage>
<pub-id pub-id-type="pmid">26358192</pub-id>
</element-citation>
</ref>
<ref id="B45">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geirnaert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Calatayud</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grootaert</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Laukens</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Devriese</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Smagghe</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Vos</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Boon</surname>
<given-names>N</given-names>
</name>
<name>
<surname>de Wiele</surname>
<given-names>TV</given-names>
</name>
</person-group>
<year>2017</year>
<article-title>Butyrate-producing bacteria supplemented <italic>in vitro</italic> to Crohn’s disease patient microbiota increased butyrate production and enhanced intestinal epithelial barrier integrity</article-title>
<source/>Sci Rep
          <volume>7</volume>
<fpage>11450</fpage>
<pub-id pub-id-type="pmid">28904372</pub-id>
</element-citation>
</ref>
<ref id="B46">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gertsman</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Gangoiti</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Nyhan</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Barshop</surname>
<given-names>BA</given-names>
</name>
</person-group>
<year>2015</year>
<article-title>Perturbations of tyrosine metabolism promote the indolepyruvate pathway via tryptophan in host and microbiome</article-title>
<source/>Mol Genet Metab
          <volume>114</volume>
<fpage>431</fpage>
<lpage>437</lpage>
<pub-id pub-id-type="pmid">25680927</pub-id>
</element-citation>
</ref>
<ref id="B47">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gill</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Pop</surname>
<given-names>M</given-names>
</name>
<name>
<surname>DeBoy</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Eckburg</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Turnbaugh</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Samuel</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Relman</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Fraser-Liggett</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>KE</given-names>
</name>
</person-group>
<year>2006</year>
<article-title>Metagenomic analysis of the human distal gut microbiome</article-title>
<source/>Science
          <volume>312</volume>
<fpage>1355</fpage>
<lpage>1359</lpage>
<pub-id pub-id-type="pmid">16741115</pub-id>
</element-citation>
</ref>
<ref id="B48">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodrich</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Davenport</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Waters</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Ley</surname>
<given-names>RE</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>Cross-species comparisons of host genetic associations with the microbiome</article-title>
<source/>Science
          <volume>352</volume>
<fpage>532</fpage>
<lpage>535</lpage>
<pub-id pub-id-type="pmid">27126034</pub-id>
</element-citation>
</ref>
<ref id="B49">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gregory</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Buffa</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Org</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Levison</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>DiDonato</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<year>2015</year>
<article-title>Transmission of atherosclerosis susceptibility with gut microbial transplantation</article-title>
<source/>J Biol Chem
          <volume>290</volume>
<fpage>5647</fpage>
<lpage>5660</lpage>
<pub-id pub-id-type="pmid">25550161</pub-id>
</element-citation>
</ref>
<ref id="B50">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grenham</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Dinan</surname>
<given-names>TG</given-names>
</name>
</person-group>
<year>2011</year>
<article-title>Brain–gut–microbe communication in health and disease</article-title>
<source/>Front Physiol
          <volume>2011</volume>
<fpage>94</fpage>
</element-citation>
</ref>
<ref id="B51">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gustot</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Durand</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lebrec</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Moreau</surname>
<given-names>R</given-names>
</name>
</person-group>
<year>2009</year>
<article-title>Severe sepsis in cirrhosis</article-title>
<source/>Hepatol Baltim Md
          <volume>50</volume>
<fpage>2022</fpage>
<lpage>2033</lpage>
</element-citation>
</ref>
<ref id="B52">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Häberle</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Boddaert</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Burlina</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chakrapani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dixon</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Huemer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Karall</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Martinelli</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Crespo</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Santer</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<year>2012</year>
<article-title>Suggested guidelines for the diagnosis and management of urea cycle disorders</article-title>
<source/>Orphanet J Rare Dis
          <volume>7</volume>
<fpage>32</fpage>
<pub-id pub-id-type="pmid">22642880</pub-id>
</element-citation>
</ref>
<ref id="B53">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>YB</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>MS</given-names>
</name>
</person-group>
<year>2014</year>
<article-title>Possible additional antidepressant-like mechanism of sodium butyrate: targeting the hippocampus</article-title>
<source/>Neuropharmacology
          <volume>81</volume>
<fpage>292</fpage>
<lpage>302</lpage>
<pub-id pub-id-type="pmid">24607816</pub-id>
</element-citation>
</ref>
<ref id="B54">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henao-Mejia</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Elinav</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mehal</surname>
<given-names>WZ</given-names>
</name>
<name>
<surname>Strowig</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Thaiss</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Kau</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Eisenbarth</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Jurczak</surname>
<given-names>MJ</given-names>
</name>
<etal></etal>
</person-group>
<year>2012</year>
<article-title>Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity</article-title>
<source/>Nature
          <volume>482</volume>
<fpage>179</fpage>
<lpage>185</lpage>
<pub-id pub-id-type="pmid">22297845</pub-id>
</element-citation>
</ref>
<ref id="B55">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hiergeist</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gläsner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Reischl</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Gessner</surname>
<given-names>A</given-names>
</name>
</person-group>
<year>2015</year>
<article-title>Analyses of intestinal microbiota: Culture <italic>vs.</italic> sequencing</article-title>
<source/>ILAR J
          <volume>56</volume>
<fpage>228</fpage>
<lpage>240</lpage>
<pub-id pub-id-type="pmid">26323632</pub-id>
</element-citation>
</ref>
<ref id="B56">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoban</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Stilling</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Shanahan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dinan</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Claesson</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>JF</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>Regulation of prefrontal cortex myelination by the microbiota</article-title>
<source/>Transl Psychiatry
          <volume>6</volume>
<fpage>e774</fpage>
<pub-id pub-id-type="pmid">27045844</pub-id>
</element-citation>
</ref>
<ref id="B57">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>Human Microbiome Project Consortium</collab>
</person-group>
<year>2012</year>
<article-title>Structure, function and diversity of the healthy human microbiome</article-title>
<source/>Nature
          <volume>486</volume>
<fpage>207</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="pmid">22699609</pub-id>
</element-citation>
</ref>
<ref id="B58">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacqueline</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Brazier</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Faugère</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Renaud</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Roche</surname>
<given-names>B</given-names>
</name>
</person-group>
<year>2017</year>
<article-title>Can intestinal microbiota be associated with non-intestinal cancers?</article-title>
<source/>Sci Rep
          <volume>7</volume>
<fpage>12722</fpage>
<pub-id pub-id-type="pmid">28983086</pub-id>
</element-citation>
</ref>
<ref id="B59">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janssen</surname>
<given-names>AWF</given-names>
</name>
<name>
<surname>Kersten</surname>
<given-names>S</given-names>
</name>
</person-group>
<year>2015</year>
<article-title>The role of the gut microbiota in metabolic health</article-title>
<source/>FASEB J
          <volume>29</volume>
<fpage>3111</fpage>
<lpage>3123</lpage>
<pub-id pub-id-type="pmid">25921831</pub-id>
</element-citation>
</ref>
<ref id="B60">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiménez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cervantes-García</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Muñoz</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>García</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Haro</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Salinas</surname>
<given-names>E</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>Novel mechanisms underlying the therapeutic effect of glycomacropeptide on allergy: Change in gut microbiota, upregulation of TGF-β, and inhibition of mast cells</article-title>
<source/>Int Arch Allergy Immunol
          <volume>171</volume>
<fpage>217</fpage>
<lpage>226</lpage>
<pub-id pub-id-type="pmid">28049206</pub-id>
</element-citation>
</ref>
<ref id="B61">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kakihana</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fujioka</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Suda</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Najima</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kuwata</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sasajima</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mimura</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Morita</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sugiyama</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Nishikawa</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<year>2016</year>
<article-title>Fecal microbiota transplantation for patients with steroid-resistant acute graft-<italic>vs.</italic> -host disease of the gut</article-title>
<source/>Blood
          <volume>128</volume>
<fpage>2083</fpage>
<lpage>2088</lpage>
<pub-id pub-id-type="pmid">27461930</pub-id>
</element-citation>
</ref>
<ref id="B62">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kashtanova</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Popenko</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Tkacheva</surname>
<given-names>ON</given-names>
</name>
<name>
<surname>Tyakht</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Alexeev</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Boytsov</surname>
<given-names>SA</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>Association between the gut microbiota and diet: Fetal life, early childhood, and further life</article-title>
<source/>Nutrition
          <volume>32</volume>
<fpage>620</fpage>
<lpage>627</lpage>
<pub-id pub-id-type="pmid">26946974</pub-id>
</element-citation>
</ref>
<ref id="B63">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koeth</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Levison</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Buffa</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Org</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sheehy</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Britt</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<year>2013</year>
<article-title>Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis</article-title>
<source/>Nat Med
          <volume>19</volume>
<fpage>576</fpage>
<lpage>585</lpage>
<pub-id pub-id-type="pmid">23563705</pub-id>
</element-citation>
</ref>
<ref id="B64">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>De Vadder</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kovatcheva-Datchary</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bäckhed</surname>
<given-names>F</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites</article-title>
<source/>Cell
          <volume>165</volume>
<fpage>1332</fpage>
<lpage>1345</lpage>
<pub-id pub-id-type="pmid">27259147</pub-id>
</element-citation>
</ref>
<ref id="B65">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lanpher</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Brunetti-Pierri</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>B</given-names>
</name>
</person-group>
<year>2006</year>
<article-title>Inborn errors of metabolism: The flux from Mendelian to complex diseases</article-title>
<source/>Nat Rev Genet
          <volume>7</volume>
<fpage>449</fpage>
<lpage>460</lpage>
<pub-id pub-id-type="pmid">16708072</pub-id>
</element-citation>
</ref>
<ref id="B66">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Larsen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Vogensen</surname>
<given-names>FK</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>FWJ van den</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Andreasen</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Al-Soud</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Sørensen</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Jakobsen</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2010</year>
<article-title>Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults</article-title>
<source/>PLoS One
          <volume>5</volume>
<fpage>e9085</fpage>
<pub-id pub-id-type="pmid">20140211</pub-id>
</element-citation>
</ref>
<ref id="B67">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le Poul</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Loison</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Struyf</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Springael</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Lannoy</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Decobecq</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Brezillon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dupriez</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Vassart</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Van Damme</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<year>2003</year>
<article-title>Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation</article-title>
<source/>J Biol Chem
          <volume>278</volume>
<fpage>25481</fpage>
<lpage>25489</lpage>
<pub-id pub-id-type="pmid">12711604</pub-id>
</element-citation>
</ref>
<ref id="B68">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leber</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Mayrhauser</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Rybczynski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stadlbauer</surname>
<given-names>V</given-names>
</name>
</person-group>
<year>2009</year>
<article-title>Innate immune dysfunction in acute and chronic liver disease</article-title>
<source/>Wien Klin Wochenschr
          <volume>121</volume>
<fpage>732</fpage>
<lpage>744</lpage>
<pub-id pub-id-type="pmid">20047110</pub-id>
</element-citation>
</ref>
<ref id="B69">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Sokol</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<year>2015</year>
<article-title>Intestinal microbiota, lipids and the pathogenesis of intestinal failure-associated liver disease</article-title>
<source/>J Pediatr
          <volume>167</volume>
<fpage>519</fpage>
<lpage>526</lpage>
<pub-id pub-id-type="pmid">26130113</pub-id>
</element-citation>
</ref>
<ref id="B70">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>JM</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>The microbiota-gut-brain axis and its potential therapeutic role in autism spectrum disorder</article-title>
<source/>Neuroscience
          <volume>324</volume>
<fpage>131</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="pmid">26964681</pub-id>
</element-citation>
</ref>
<ref id="B71">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<year>2015a</year>
<article-title>Neuroprotective effects of <italic>Clostridium butyricum</italic> against vascular dementia in mice via metabolic butyrate</article-title>
<source/>BioMed Res Int
          <volume>2015</volume>
<fpage>412946</fpage>
<pub-id pub-id-type="pmid">26523278</pub-id>
</element-citation>
</ref>
<ref id="B72">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>TX</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>HT</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>SY</given-names>
</name>
</person-group>
<year>2015b</year>
<article-title>Intestinal microbiota metabolism and atherosclerosis</article-title>
<source/>Chin Med J
          <volume>128</volume>
<fpage>2805</fpage>
<lpage>2811</lpage>
<pub-id pub-id-type="pmid">26481750</pub-id>
</element-citation>
</ref>
<ref id="B73">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lloyd-Price</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Abu-Ali</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Huttenhower</surname>
<given-names>C</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>The healthy human microbiome</article-title>
<source/>Genome Med
          <volume>8</volume>
<fpage>51</fpage>
<pub-id pub-id-type="pmid">27122046</pub-id>
</element-citation>
</ref>
<ref id="B74">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez-Legarrea</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fuller</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Zulet</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Caterson</surname>
<given-names>ID</given-names>
</name>
</person-group>
<year>2014</year>
<article-title>The influence of Mediterranean, carbohydrate and high protein diets on gut microbiota composition in the treatment of obesity and associated inflammatory state</article-title>
<source/>Asia Pac J Clin Nutr
          <volume>23</volume>
<fpage>360</fpage>
<lpage>368</lpage>
<pub-id pub-id-type="pmid">25164445</pub-id>
</element-citation>
</ref>
<ref id="B75">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Louis</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Holtrop</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Flint</surname>
<given-names>HJ</given-names>
</name>
</person-group>
<year>2010</year>
<article-title>Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA:acetate CoA-transferase gene</article-title>
<source/>Environ Microbiol
          <volume>12</volume>
<fpage>304</fpage>
<lpage>314</lpage>
<pub-id pub-id-type="pmid">19807780</pub-id>
</element-citation>
</ref>
<ref id="B76">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacDonald</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cochrane</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wopereis</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Loveridge</surname>
<given-names>N</given-names>
</name>
</person-group>
<year>2011</year>
<article-title>Specific prebiotics in a formula for infants with Phenylketonuria</article-title>
<source/>Mol Genet Metab
          <volume>104</volume>
<issue>Suppl</issue>
<fpage>S55</fpage>
<lpage>S59</lpage>
<pub-id pub-id-type="pmid">21967856</pub-id>
</element-citation>
</ref>
<ref id="B77">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mackay</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>McEntyre</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Henderson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lever</surname>
<given-names>M</given-names>
</name>
<name>
<surname>George</surname>
<given-names>PM</given-names>
</name>
</person-group>
<year>2011</year>
<article-title>Trimethylaminuria: Causes and diagnosis of a socially distressing condition</article-title>
<source/>Clin Biochem Rev
          <volume>32</volume>
<fpage>33</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="pmid">21451776</pub-id>
</element-citation>
</ref>
<ref id="B78">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Macpherson</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Heikenwalder</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ganal-Vonarburg</surname>
<given-names>SC</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>The liver at the nexus of host-microbial interactions</article-title>
<source/>Cell Host Microbe
          <volume>20</volume>
<fpage>561</fpage>
<lpage>571</lpage>
<pub-id pub-id-type="pmid">27832587</pub-id>
</element-citation>
</ref>
<ref id="B79">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Madigan</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Martinko</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Brock</surname>
<given-names>TD</given-names>
</name>
</person-group>
<year>2006</year>
<source/>Brock Biology of Microorganisms
          <publisher-name>Pearson Prentice Hall</publisher-name>
<publisher-loc>Nova Jersey</publisher-loc>
<fpage>992</fpage>
</element-citation>
</ref>
<ref id="B80">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marchesi</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Ravel</surname>
<given-names>J</given-names>
</name>
</person-group>
<year>2015</year>
<article-title>The vocabulary of microbiome research: A proposal</article-title>
<source/>Microbiome
          <volume>3</volume>
<fpage>31</fpage>
<pub-id pub-id-type="pmid">26229597</pub-id>
</element-citation>
</ref>
<ref id="B81">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martínez</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Stegen</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Maldonado-Gómez</surname>
<given-names>MX</given-names>
</name>
<name>
<surname>Eren</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Siba</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Greenhill</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>J</given-names>
</name>
</person-group>
<year>2015</year>
<article-title>The gut microbiota of rural Papua New Guineans: Composition, diversity patterns, and ecological processes</article-title>
<source/>Cell Rep
          <volume>11</volume>
<fpage>527</fpage>
<lpage>538</lpage>
<comment>d</comment>
<pub-id pub-id-type="pmid">25892234</pub-id>
</element-citation>
</ref>
<ref id="B82">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maslowski</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Mackay</surname>
<given-names>CR</given-names>
</name>
</person-group>
<year>2011</year>
<article-title>Diet, gut microbiota and immune responses</article-title>
<source/>Nat Immunol
          <volume>12</volume>
<fpage>5</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">21169997</pub-id>
</element-citation>
</ref>
<ref id="B83">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maukonen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Saarela</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2015</year>
<article-title>Human gut microbiota: does diet matter?</article-title>
<source/>Proc Nutr Soc
          <volume>74</volume>
<fpage>23</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="pmid">25156389</pub-id>
</element-citation>
</ref>
<ref id="B84">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mayer</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mazmanian</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Tillisch</surname>
<given-names>K</given-names>
</name>
</person-group>
<year>2014</year>
<article-title>Gut microbes and the Bbrain: Paradigm shift in neuroscience</article-title>
<source/>J Neurosci
          <volume>34</volume>
<fpage>15490</fpage>
<lpage>15496</lpage>
<pub-id pub-id-type="pmid">25392516</pub-id>
</element-citation>
</ref>
<ref id="B85">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Della Casa</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Balivo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Minopoli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Salerno</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Andria</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Parenti</surname>
<given-names>G</given-names>
</name>
</person-group>
<year>2014</year>
<article-title>Involvement of endocrine system in a patient affected by glycogen storage disease 1b: speculation on the role of autoimmunity</article-title>
<source/>Ital J Pediatr
          <volume>40</volume>
<fpage>30</fpage>
<pub-id pub-id-type="pmid">24646511</pub-id>
</element-citation>
</ref>
<ref id="B86">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mistry</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Bukhari</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>AM</given-names>
</name>
</person-group>
<year>2013</year>
<article-title>Alkaptonuria</article-title>
<source/>Rare Dis
          <volume>1</volume>
<fpage>e27475</fpage>
<pub-id pub-id-type="pmid">25003018</pub-id>
</element-citation>
</ref>
<ref id="B87">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moloney</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Desbonnet</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Dinan</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>JF</given-names>
</name>
</person-group>
<year>2014</year>
<article-title>The microbiome: Stress, health and disease</article-title>
<source/>Mamm Genome
          <volume>5</volume>
<fpage>49</fpage>
<lpage>74</lpage>
</element-citation>
</ref>
<ref id="B88">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montagner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Korecka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Polizzi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lippi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Blum</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Canlet</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tremblay-Franco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gautier-Stein</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Burcelin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yen</surname>
<given-names>YC</given-names>
</name>
<etal></etal>
</person-group>
<year>2016</year>
<article-title>Hepatic circadian clock oscillators and nuclear receptors integrate microbiome-derived signals</article-title>
<source/>Sci Rep
          <volume>6</volume>
<fpage>20127</fpage>
<pub-id pub-id-type="pmid">26879573</pub-id>
</element-citation>
</ref>
<ref id="B89">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakao</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Moriya</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Furuyama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Niederman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sugiya</surname>
<given-names>H</given-names>
</name>
</person-group>
<year>1998</year>
<article-title>Propionic acid stimulates superoxide generation in human neutrophils</article-title>
<source/>Cell Biol Int
          <volume>22</volume>
<fpage>331</fpage>
<lpage>337</lpage>
<pub-id pub-id-type="pmid">10198152</pub-id>
</element-citation>
</ref>
<ref id="B90">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nankova</surname>
<given-names>BB</given-names>
</name>
<name>
<surname>Agarwal</surname>
<given-names>R</given-names>
</name>
<name>
<surname>MacFabe</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>La Gamma</surname>
<given-names>EF</given-names>
</name>
</person-group>
<year>2014</year>
<article-title>Enteric bacterial metabolites propionic and butyric acid modulate gene expression, including CREB-dependent catecholaminergic neurotransmission, in PC12 cells—possible relevance to autism spectrum disorders</article-title>
<source/>PLoS One
          <volume>9</volume>
<fpage>e103740</fpage>
<pub-id pub-id-type="pmid">25170769</pub-id>
</element-citation>
</ref>
<ref id="B91">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma R</surname>
<given-names>Neelima</given-names>
</name>
<name>
<surname>Rajput</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>B</given-names>
</name>
</person-group>
<year>2013</year>
<article-title>Chemical and functional properties of glycomacropeptide (GMP) and its role in the detection of cheese whey adulteration in milk: a review</article-title>
<source/>Dairy Sci Technol
          <volume>93</volume>
<fpage>21</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="pmid">23396893</pub-id>
</element-citation>
</ref>
<ref id="B92">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ney</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Stroup</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Clayton</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Murali</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Rohr</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>HL</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>Glycomacropeptide for nutritional management of phenylketonuria: a randomized, controlled, crossover trial</article-title>
<source/>Am J Clin Nutr
          <volume>104</volume>
<fpage>334</fpage>
<lpage>345</lpage>
<pub-id pub-id-type="pmid">27413125</pub-id>
</element-citation>
</ref>
<ref id="B93">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ney</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Murali</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Stroup</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sawin</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Rohr</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>HL</given-names>
</name>
</person-group>
<year>2017</year>
<article-title>Metabolomic changes demonstrate reduced bioavailability of tyrosine and altered metabolism of tryptophan via the kynurenine pathway with ingestion of medical foods in phenylketonuria</article-title>
<source/>Mol Genet Metab
          <volume>121</volume>
<fpage>96</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="pmid">28400091</pub-id>
</element-citation>
</ref>
<ref id="B94">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>NHT</given-names>
</name>
<name>
<surname>Morland</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Rise</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Storm-Mathisen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gundersen</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Hassel</surname>
<given-names>B</given-names>
</name>
</person-group>
<year>2007</year>
<article-title>Propionate increases neuronal histone acetylation, but is metabolized oxidatively by glia. Relevance for propionic acidemia</article-title>
<source/>J Neurochem
          <volume>101</volume>
<fpage>806</fpage>
<lpage>814</lpage>
<pub-id pub-id-type="pmid">17286595</pub-id>
</element-citation>
</ref>
<ref id="B95">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ochoa-Repáraz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kasper</surname>
<given-names>LH</given-names>
</name>
</person-group>
<year>2014</year>
<article-title>Gut microbiome and the risk factors in central nervous system autoimmunity</article-title>
<source/>FEBS Lett
          <volume>588</volume>
<fpage>4214</fpage>
<lpage>4222</lpage>
<pub-id pub-id-type="pmid">25286403</pub-id>
</element-citation>
</ref>
<ref id="B96">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Odamaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sugahara</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hashikura</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Abe</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Osawa</surname>
<given-names>R</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study</article-title>
<source/>BMC Microbiol
          <volume>16</volume>
<fpage>90</fpage>
<pub-id pub-id-type="pmid">27220822</pub-id>
</element-citation>
</ref>
<ref id="B97">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Omran</surname>
<given-names>YA</given-names>
</name>
<name>
<surname>Aziz</surname>
<given-names>Q</given-names>
</name>
</person-group>
<year>2014</year>
<chapter-title>The Brain-Gut Axis in Health and Disease</chapter-title>
<source/>In: Lyte M and Cryan JF (eds) Microbial Endocrinology: The Microbiota-Gut-Brain Axis in Health and Disease
          <publisher-name>Springer</publisher-name>
<publisher-loc>New York</publisher-loc>
<fpage>135</fpage>
<lpage>153</lpage>
</element-citation>
</ref>
<ref id="B98">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oriach</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Stanton</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Dinan</surname>
<given-names>TG</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>Food for thought: The role of nutrition in the microbiota-gut–brain axis</article-title>
<source/>Clin Nutr Exp
          <volume>6</volume>
<fpage>25</fpage>
<lpage>38</lpage>
</element-citation>
</ref>
<ref id="B99">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ottman</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Smidt</surname>
<given-names>H</given-names>
</name>
<name>
<surname>de Vos</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Belzer</surname>
<given-names>C</given-names>
</name>
</person-group>
<year>2012</year>
<article-title>The function of our microbiota: Who is out there and what do they do?</article-title>
<source/>Front Cell Infect Microbiol
          <volume>2</volume>
<fpage>104</fpage>
<pub-id pub-id-type="pmid">22919693</pub-id>
</element-citation>
</ref>
<ref id="B100">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parracho</surname>
<given-names>HMRT</given-names>
</name>
<name>
<surname>Bingham</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Gibson</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>McCartney</surname>
<given-names>AL</given-names>
</name>
</person-group>
<year>2005</year>
<article-title>Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children</article-title>
<source/>J Med Microbiol
          <volume>54</volume>
<fpage>987</fpage>
<lpage>991</lpage>
<pub-id pub-id-type="pmid">16157555</pub-id>
</element-citation>
</ref>
<ref id="B101">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pérez</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Desviat</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Gómez-Puertas</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Martínez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Ugarte</surname>
<given-names>M</given-names>
</name>
</person-group>
<year>2005</year>
<article-title>Kinetic and stability analysis of PKU mutations identified in BH4-responsive patients</article-title>
<source/>Mol Genet Metab
          <volume>86</volume>
<issue>Suppl1</issue>
<fpage>S11</fpage>
<lpage>S16</lpage>
<pub-id pub-id-type="pmid">16091306</pub-id>
</element-citation>
</ref>
<ref id="B102">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petra</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Panagiotidou</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hatziagelaki</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Conti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Theoharides</surname>
<given-names>TC</given-names>
</name>
</person-group>
<year>2015</year>
<article-title>Gut-microbiota-brain axis and its effect on neuropsychiatric disorders with suspected immune dysregulation</article-title>
<source/>Clin Ther
          <volume>37</volume>
<fpage>984</fpage>
<lpage>995</lpage>
<pub-id pub-id-type="pmid">26046241</pub-id>
</element-citation>
</ref>
<ref id="B103">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pierre</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Pellerin</surname>
<given-names>L</given-names>
</name>
</person-group>
<year>2005</year>
<article-title>Monocarboxylate transporters in the central nervous system: distribution, regulation and function</article-title>
<source/>J Neurochem
          <volume>94</volume>
<fpage>1</fpage>
<lpage>14</lpage>
</element-citation>
</ref>
<ref id="B104">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinheiro de Oliveira</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mendes</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Dobbler</surname>
<given-names>PT</given-names>
</name>
<name>
<surname>Mai</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Pylro</surname>
<given-names>VS</given-names>
</name>
<name>
<surname>Waugh</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Vairo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Refosco</surname>
<given-names>LF</given-names>
</name>
<name>
<surname>Roesch</surname>
<given-names>LFW</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>IVD</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>Phenylketonuria and gut microbiota: A controlled study based on next-generation sequencing</article-title>
<source/>PloS One
          <volume>11</volume>
<fpage>e0157513</fpage>
<pub-id pub-id-type="pmid">27336782</pub-id>
</element-citation>
</ref>
<ref id="B105">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Powell</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Talley</surname>
<given-names>NJ</given-names>
</name>
</person-group>
<year>2017</year>
<article-title>The mucosal immune system: Master regulator of bidirectional gut-brain communications</article-title>
<source/>Nat Rev Gastroenterol Hepatol
          <volume>14</volume>
<fpage>143</fpage>
<lpage>159</lpage>
<pub-id pub-id-type="pmid">28096541</pub-id>
</element-citation>
</ref>
<ref id="B106">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rashidi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Khoruts</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Weisdorf</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<year>2017</year>
<article-title>Infection followed by graft-<italic>vs.</italic> -host disease: Pathogenic role of antibiotics</article-title>
<source/>Biol Blood Marrow Transplant
          <volume>23</volume>
<fpage>1038</fpage>
<lpage>1039</lpage>
<pub-id pub-id-type="pmid">28257799</pub-id>
</element-citation>
</ref>
<ref id="B107">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rautava</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kainonen</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Salminen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Isolauri</surname>
<given-names>E</given-names>
</name>
</person-group>
<year>2012</year>
<article-title>Maternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of eczema in the infant</article-title>
<source/>J Allergy Clin Immunol
          <volume>130</volume>
<fpage>1355</fpage>
<lpage>1360</lpage>
<pub-id pub-id-type="pmid">23083673</pub-id>
</element-citation>
</ref>
<ref id="B108">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reigstad</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Salmonson</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Rainey</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Szurszewski</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Linden</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Sonnenburg</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Farrugia</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kashyap</surname>
<given-names>PC</given-names>
</name>
</person-group>
<year>2015</year>
<article-title>Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells</article-title>
<source/>FASEB J
          <volume>29</volume>
<fpage>1395</fpage>
<lpage>1403</lpage>
<pub-id pub-id-type="pmid">25550456</pub-id>
</element-citation>
</ref>
<ref id="B109">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rooks</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Garrett</surname>
<given-names>WS</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>Gut microbiota, metabolites and host immunity</article-title>
<source/>Nat Rev Immunol
          <volume>16</volume>
<fpage>341</fpage>
<lpage>352</lpage>
<pub-id pub-id-type="pmid">27231050</pub-id>
</element-citation>
</ref>
<ref id="B110">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Routy</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Letendre</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Enot</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Chénard-Poirier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mehraj</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Séguin</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Guenda</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gagnon</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Woerther</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Ghez</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<year>2017</year>
<article-title>The influence of gut-decontamination prophylactic antibiotics on acute graft-<italic>vs.</italic> -host disease and survival following allogeneic hematopoietic stem cell transplantation</article-title>
<source/>Oncoimmunology
          <volume>6</volume>
<fpage>e1258506</fpage>
<pub-id pub-id-type="pmid">28197380</pub-id>
</element-citation>
</ref>
<ref id="B111">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rowan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Docherty</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Calvin Coffey</surname>
<given-names>J</given-names>
</name>
<name>
<surname>O’Connell</surname>
<given-names>PR</given-names>
</name>
</person-group>
<year>2010</year>
<article-title>Desulfovibrio bacterial species are increased in ulcerative colitis</article-title>
<source/>Dis Colon Rectum
          <volume>53</volume>
<fpage>1530</fpage>
<lpage>1536</lpage>
<pub-id pub-id-type="pmid">20940602</pub-id>
</element-citation>
</ref>
<ref id="B112">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roy</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Kien</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Bouthillier</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>E</given-names>
</name>
</person-group>
<year>2006</year>
<article-title>Short-chain fatty acids: Ready for prime time?</article-title>
<source/>Nutr Clin Pract
          <volume>21</volume>
<fpage>351</fpage>
<lpage>366</lpage>
<pub-id pub-id-type="pmid">16870803</pub-id>
</element-citation>
</ref>
<ref id="B113">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sahoo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Franzson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jonsson</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>I</given-names>
</name>
</person-group>
<year>2012</year>
<article-title>A compendium of inborn errors of metabolism mapped onto the human metabolic network</article-title>
<source/>Mol Biosyst
          <volume>8</volume>
<fpage>2545</fpage>
<lpage>2558</lpage>
<pub-id pub-id-type="pmid">22699794</pub-id>
</element-citation>
</ref>
<ref id="B114">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sampson</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Debelius</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Thron</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Janssen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shastri</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Ilhan</surname>
<given-names>ZE</given-names>
</name>
<name>
<surname>Challis</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schretter</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Rocha</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gradinaru</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<year>2016</year>
<article-title>Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease</article-title>
<source/>Cell
          <volume>167</volume>
<fpage>1469</fpage>
<lpage>1480.e12</lpage>
<pub-id pub-id-type="pmid">27912057</pub-id>
</element-citation>
</ref>
<ref id="B115">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandler</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Finegold</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Bolte</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Buchanan</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Maxwell</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Väisänen</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Wexler</surname>
<given-names>HM</given-names>
</name>
</person-group>
<year>2000</year>
<article-title>Short-term benefit from oral vancomycin treatment of regressive-onset autism</article-title>
<source/>J Child Neurol
          <volume>15</volume>
<fpage>429</fpage>
<lpage>435</lpage>
<pub-id pub-id-type="pmid">10921511</pub-id>
</element-citation>
</ref>
<ref id="B116">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santra</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Preece</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Hulton</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>McKiernan</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<year>2008</year>
<article-title>Renal tubular function in children with tyrosinaemia type I treated with nitisinone</article-title>
<source/>J Inherit Metab Dis
          <volume>31</volume>
<fpage>399</fpage>
<lpage>402</lpage>
<pub-id pub-id-type="pmid">18509744</pub-id>
</element-citation>
</ref>
<ref id="B117">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sawin</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>De Wolfe</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Aktas</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Stroup</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Murali</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Steele</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Ney</surname>
<given-names>DM</given-names>
</name>
</person-group>
<year>2015</year>
<article-title>Glycomacropeptide is a prebiotic that reduces Desulfovibrio bacteria, increases cecal short-chain fatty acids, and is anti-inflammatory in mice</article-title>
<source/>Am J Physiol Gastrointest Liver Physiol
          <volume>309</volume>
<fpage>G590</fpage>
<lpage>601</lpage>
<pub-id pub-id-type="pmid">26251473</pub-id>
</element-citation>
</ref>
<ref id="B118">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>IV</given-names>
</name>
<name>
<surname>Souza</surname>
<given-names>CFM</given-names>
</name>
<name>
<surname>Giugliani</surname>
<given-names>R</given-names>
</name>
</person-group>
<year>2008</year>
<article-title>Treatment of inborn errors of metabolism</article-title>
<source/>J Pediatr
          <volume>84</volume>
<fpage>S8</fpage>
<lpage>S19</lpage>
</element-citation>
</ref>
<ref id="B119">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Segata</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Izard</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Waldron</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gevers</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Miropolsky</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Garrett</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Huttenhower</surname>
<given-names>C</given-names>
</name>
</person-group>
<year>2011</year>
<article-title>Metagenomic biomarker discovery and explanation</article-title>
<source/>Genome Biol
          <volume>12</volume>
<fpage>R60</fpage>
<pub-id pub-id-type="pmid">21702898</pub-id>
</element-citation>
</ref>
<ref id="B120">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sender</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fuchs</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Milo</surname>
<given-names>R</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>Revised estimates for the number of human and bacteria cells in the body</article-title>
<source/>PLoS Biol
          <volume>14</volume>
<fpage>e1002533</fpage>
<pub-id pub-id-type="pmid">27541692</pub-id>
</element-citation>
</ref>
<ref id="B121">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shafquat</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Joice</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Simmons</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Huttenhower</surname>
<given-names>C</given-names>
</name>
</person-group>
<year>2014</year>
<article-title>Functional and phylogenetic assembly of microbial communities in the human microbiome</article-title>
<source/>Trends Microbiol
          <volume>22</volume>
<fpage>261</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">24618403</pub-id>
</element-citation>
</ref>
<ref id="B122">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharer</surname>
<given-names>JD</given-names>
</name>
</person-group>
<year>2011</year>
<article-title>An overview of biochemical genetics</article-title>
<source/>Curr Protoc Hum Genet Chapter
          <volume>17</volume>
<fpage>17.1</fpage>
</element-citation>
</ref>
<ref id="B123">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharon</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Debelius</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dorrestein</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Mazmanian</surname>
<given-names>SK</given-names>
</name>
</person-group>
<year>2014</year>
<article-title>Specialized metabolites from the microbiome in health and disease</article-title>
<source/>Cell Metab
          <volume>20</volume>
<fpage>719</fpage>
<lpage>730</lpage>
<pub-id pub-id-type="pmid">25440054</pub-id>
</element-citation>
</ref>
<ref id="B124">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shaw</surname>
<given-names>W</given-names>
</name>
</person-group>
<year>2010</year>
<article-title>Increased urinary excretion of a 3-(3-hydroxyphenyl)-3-hydroxypropionic acid (HPHPA), an abnormal phenylalanine metabolite of <italic>Clostridia</italic> spp. in the gastrointestinal tract, in urine samples from patients with autism and schizophrenia</article-title>
<source/>Nutr Neurosci
          <volume>13</volume>
<fpage>135</fpage>
<lpage>143</lpage>
<pub-id pub-id-type="pmid">20423563</pub-id>
</element-citation>
</ref>
<ref id="B125">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheth</surname>
<given-names>RU</given-names>
</name>
<name>
<surname>Cabral</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>HH</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>Manipulating bacterial communities by <italic>in situ</italic> microbiome engineering</article-title>
<source/>Trends Genet
          <volume>32</volume>
<fpage>189</fpage>
<lpage>200</lpage>
<pub-id pub-id-type="pmid">26916078</pub-id>
</element-citation>
</ref>
<ref id="B126">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sirrs</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Faghfoury</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Geberhiwot</surname>
<given-names>T</given-names>
</name>
</person-group>
<year>2013</year>
<article-title>Barriers to transplantation in adults with inborn errors of metabolism</article-title>
<source/>JIMD Rep
          <volume>8</volume>
<fpage>139</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="pmid">23430530</pub-id>
</element-citation>
</ref>
<ref id="B127">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Slykerman</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Hood</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Wickens</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>JMD</given-names>
</name>
<name>
<surname>Barthow</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rowden</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Crane</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<year>2017</year>
<article-title>Effect of <italic>Lactobacillus rhamnosus</italic> HN001 in pregnancy on postpartum symptoms of depression and anxiety: A randomised double-blind placebo-controlled trial</article-title>
<source/>EBioMedicine
          <volume>24</volume>
<fpage>159</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="pmid">28943228</pub-id>
</element-citation>
</ref>
<ref id="B128">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Finegold</surname>
<given-names>SM</given-names>
</name>
</person-group>
<year>2004</year>
<article-title>Real-Time PCR auantitation of Clostridia in feces of autistic children</article-title>
<source/>Appl Environ Microbiol
          <volume>70</volume>
<fpage>6459</fpage>
<lpage>6465</lpage>
<pub-id pub-id-type="pmid">15528506</pub-id>
</element-citation>
</ref>
<ref id="B129">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sonnenburg</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Sonnenburg</surname>
<given-names>JL</given-names>
</name>
</person-group>
<year>2014</year>
<article-title>Starving our microbial self: The deleterious consequences of a diet deficient in microbiota-accessible carbohydrates</article-title>
<source/>Cell Metab
          <volume>20</volume>
<fpage>779</fpage>
<lpage>786</lpage>
<pub-id pub-id-type="pmid">25156449</pub-id>
</element-citation>
</ref>
<ref id="B130">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spindelboeck</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Uhl</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kashofer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Aigelsreiter</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zinke-Cerwenka</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Mulabecirovic</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kump</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Halwachs</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gorkiewicz</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<year>2017</year>
<article-title>Repeated fecal microbiota transplantations attenuate diarrhea and lead to sustained changes in the fecal microbiota in acute, refractory gastrointestinal graft-<italic>vs.</italic> -host-disease</article-title>
<source/>Haematologica
          <volume>102</volume>
<fpage>e210</fpage>
<lpage>e213</lpage>
<pub-id pub-id-type="pmid">28154090</pub-id>
</element-citation>
</ref>
<ref id="B131">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Staffas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Burgos da Silva</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van den Brink</surname>
<given-names>MRM</given-names>
</name>
</person-group>
<year>2017</year>
<article-title>The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-<italic>vs.</italic> -host disease</article-title>
<source/>Blood
          <volume>129</volume>
<fpage>927</fpage>
<lpage>933</lpage>
<pub-id pub-id-type="pmid">27940475</pub-id>
</element-citation>
</ref>
<ref id="B132">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steenbergen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sellaro</surname>
<given-names>R</given-names>
</name>
<name>
<surname>van Hemert</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bosch</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Colzato</surname>
<given-names>LS</given-names>
</name>
</person-group>
<year>2015</year>
<article-title>A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood</article-title>
<source/>Brain Behav Immun
          <volume>48</volume>
<fpage>258</fpage>
<lpage>264</lpage>
<pub-id pub-id-type="pmid">25862297</pub-id>
</element-citation>
</ref>
<ref id="B133">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stilling</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>van de Wouw</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Stanton</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dinan</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>JF</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>The neuropharmacology of butyrate: The bread and butter of the microbiota-gut-brain axis?</article-title>
<source/>Neurochem Int
          <volume>99</volume>
<fpage>110</fpage>
<lpage>132</lpage>
<pub-id pub-id-type="pmid">27346602</pub-id>
</element-citation>
</ref>
<ref id="B134">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strati</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cavalieri</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Albanese</surname>
<given-names>D</given-names>
</name>
<name>
<surname>De Felice</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Donati</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hayek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jousson</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Leoncini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Renzi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Calabrò</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<year>2017</year>
<article-title>New evidences on the altered gut microbiota in autism spectrum disorders</article-title>
<source/>Microbiome
          <volume>5</volume>
<fpage>24</fpage>
<pub-id pub-id-type="pmid">28222761</pub-id>
</element-citation>
</ref>
<ref id="B135">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Korem</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zeevi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zilberman-Schapira</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Thaiss</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Maza</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Israeli</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zmora</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gilad</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Weinberger</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<year>2014</year>
<article-title>Artificial sweeteners induce glucose intolerance by altering the gut microbiota</article-title>
<source/>Nature
          <volume>514</volume>
<fpage>181</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="pmid">25231862</pub-id>
</element-citation>
</ref>
<ref id="B136">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tilg</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Grander</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Moschen</surname>
<given-names>AR</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>How does the microbiome affect liver disease?</article-title>
<source/>Clin Liver Dis
          <volume>8</volume>
<fpage>123</fpage>
<lpage>126</lpage>
</element-citation>
</ref>
<ref id="B137">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tillisch</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Labus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kilpatrick</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Stains</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ebrat</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Guyonnet</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Legrain-Raspaud</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Trotin</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Naliboff</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<year>2013</year>
<article-title>Consumption of fermented milk product with probiotic modulates brain activity</article-title>
<source/>Gastroenterology
          <volume>144</volume>
<fpage>1394</fpage>
<lpage>1401</lpage>
<pub-id pub-id-type="pmid">23474283</pub-id>
</element-citation>
</ref>
<ref id="B138">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tremaroli</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Bäckhed</surname>
<given-names>F</given-names>
</name>
</person-group>
<year>2012</year>
<article-title>Functional interactions between the gut microbiota and host metabolism</article-title>
<source/>Nature
          <volume>489</volume>
<fpage>242</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="pmid">22972297</pub-id>
</element-citation>
</ref>
<ref id="B139">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turnbaugh</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>JI</given-names>
</name>
</person-group>
<year>2009</year>
<article-title>The core gut microbiome, energy balance and obesity</article-title>
<source/>J Physiol
          <volume>587</volume>
<fpage>4153</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">19491241</pub-id>
</element-citation>
</ref>
<ref id="B140">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turnbaugh</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Ley</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Hamady</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fraser-Liggett</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>JI</given-names>
</name>
</person-group>
<year>2007</year>
<article-title>The human microbiome project: exploring the microbial part of ourselves in a changing world</article-title>
<source/>Nature
          <volume>449</volume>
<fpage>804</fpage>
<lpage>810</lpage>
<pub-id pub-id-type="pmid">17943116</pub-id>
</element-citation>
</ref>
<ref id="B141">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vinolo</surname>
<given-names>MAR</given-names>
</name>
<name>
<surname>Rodrigues</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Nachbar</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Curi</surname>
<given-names>R</given-names>
</name>
</person-group>
<year>2011</year>
<article-title>Regulation of inflammation by short chain fatty acids</article-title>
<source/>Nutrients
          <volume>3</volume>
<fpage>858</fpage>
<lpage>876</lpage>
<pub-id pub-id-type="pmid">22254083</pub-id>
</element-citation>
</ref>
<ref id="B142">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Klipfell</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Koeth</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Levison</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>DuGar</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Feldstein</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Britt</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>YM</given-names>
</name>
<etal></etal>
</person-group>
<year>2011</year>
<article-title>Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease</article-title>
<source/>Nature
          <volume>472</volume>
<fpage>57</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">21475195</pub-id>
</element-citation>
</ref>
<ref id="B143">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ley</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Volchkov</surname>
<given-names>PY</given-names>
</name>
<name>
<surname>Stranges</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Avanesyan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Stonebraker</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Szot</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Bluestone</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<year>2008</year>
<article-title>Innate immunity and intestinal microbiota in the development of Type 1 diabetes</article-title>
<source/>Nature
          <volume>455</volume>
<fpage>1109</fpage>
<lpage>1113</lpage>
<pub-id pub-id-type="pmid">18806780</pub-id>
</element-citation>
</ref>
<ref id="B144">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Hornig</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Buie</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bauman</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Cho Paik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wick</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jabado</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Hirschberg</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Lipkin</surname>
<given-names>WI</given-names>
</name>
</person-group>
<year>2011</year>
<article-title>Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism and gastrointestinal disturbances</article-title>
<source/>PloS One
          <volume>6</volume>
<fpage>e24585</fpage>
<pub-id pub-id-type="pmid">21949732</pub-id>
</element-citation>
</ref>
<ref id="B145">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Witters</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Debbold</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Crivelly</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Vande Kerckhove</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Corthouts</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Debbold</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Andersson</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Vannieuwenborg</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Geuens</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Baumgartner</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<year>2016</year>
<article-title>Autism in patients with propionic acidemia</article-title>
<source/>Mol Genet Metab
          <volume>119</volume>
<fpage>317</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="pmid">27825584</pub-id>
</element-citation>
</ref>
<ref id="B146">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>B</given-names>
</name>
</person-group>
<year>2017</year>
<article-title>Analysis of mucosa-associated microbiota in colorectal cancer</article-title>
<source/>Med Sci Monit Int Med J Exp Clin Res
          <volume>23</volume>
<fpage>4422</fpage>
<lpage>4430</lpage>
</element-citation>
</ref>
<ref id="B147">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>SQ</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>HZ</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Clemens</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Diehl</surname>
<given-names>AM</given-names>
</name>
</person-group>
<year>1997</year>
<article-title>Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of?steatohepatitis</article-title>
<source/>Proc Natl Acad Sci U S A
          <volume>94</volume>
<fpage>2557</fpage>
<lpage>2562</lpage>
<pub-id pub-id-type="pmid">9122234</pub-id>
</element-citation>
</ref>
<ref id="B148">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yatsunenko</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rey</surname>
<given-names>FE</given-names>
</name>
<name>
<surname>Manary</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Trehan</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Dominguez-Bello</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Contreras</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Magris</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hidalgo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Baldassano</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Anokhin</surname>
<given-names>AP</given-names>
</name>
<etal></etal>
</person-group>
<year>2012</year>
<article-title>Human gut microbiome viewed across age and geography</article-title>
<source/>Nature
          <volume>486</volume>
<fpage>222</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="pmid">22699611</pub-id>
</element-citation>
</ref>
<ref id="B149">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>VB</given-names>
</name>
</person-group>
<year>2017</year>
<article-title>The role of the microbiome in human health and disease: An introduction for clinicians</article-title>
<source/>BMJ
          <volume>356</volume>
<fpage>j831</fpage>
<pub-id pub-id-type="pmid">28298355</pub-id>
</element-citation>
</ref>
<ref id="B150">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zaki</surname>
<given-names>OK</given-names>
</name>
<name>
<surname>El-Wakeel</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ebeid</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ez Elarab</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Moustafa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Abdulazim</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Karara</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Elghawaby</surname>
<given-names>A</given-names>
</name>
</person-group>
<year>2016</year>
<article-title>The use of glycomacropeptide in dietary management of phenylketonuria</article-title>
<source/>J Nutr Metab
          <volume>2016</volume>
<fpage>2453027</fpage>
<pub-id pub-id-type="pmid">27313877</pub-id>
</element-citation>
</ref>
</ref-list>
<ref-list>
<title>Internet Resources</title>
<ref id="B151">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Ah Mew</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Simpson</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Gropman</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Brendan</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Lanpher</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chapman</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Summar</surname>
<given-names>ML</given-names>
</name>
</person-group>
<year>2003</year>
<chapter-title>Urea Cycle Disorders Overview. 2003 Apr 29 [Updated 2017 Jun 22]</chapter-title>
<person-group person-group-type="editor">
<name>
<surname>Adam</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Ardinger</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Pagon</surname>
<given-names>RA</given-names>
</name>
<etal></etal>
</person-group>
<source/>GeneReviews® [Internet]
          <publisher-loc>Seattle (WA)</publisher-loc>
<publisher-name>University of Washington, Seattle</publisher-name>
<fpage>1993</fpage>
<lpage>2017</lpage>
<comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK1217/">https://www.ncbi.nlm.nih.gov/books/NBK1217/</ext-link> (November 01, 2017).</comment>
</element-citation>
</ref>
<ref id="B152">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Introne</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Gahl</surname>
<given-names>WA</given-names>
</name>
</person-group>
<year>2003</year>
<chapter-title>Alkaptonuria. 2003 May 9 [Updated 2016 May 12]. In: Pagon RA, Adam MP, Ardinger HH, <italic>et al.,</italic> editors</chapter-title>
<source/>GeneReviews® [Internet]
          <publisher-loc>Seattle (WA)</publisher-loc>
<publisher-name>University of Washington, Seattle</publisher-name>
<fpage>1993</fpage>
<lpage>2017</lpage>
<comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK1454/">https://www.ncbi.nlm.nih.gov/books/NBK1454/</ext-link> (November 01, 2017)</comment>
</element-citation>
</ref>
<ref id="B153">
<element-citation publication-type="webpage">
<article-title>Metagenomics of the Human Intestinal Tract (MetaHIT)</article-title>
<comment><ext-link ext-link-type="uri" xlink:href="http://www.metahit.eu/">http://www.metahit.eu/</ext-link> (December 09, 2017)</comment>
</element-citation>
</ref>
<ref id="B154">
<element-citation publication-type="webpage">
<article-title>Online Mendelian Inheritance in Man (OMIM)</article-title>
<comment><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/OMIM">http://www.ncbi.nlm.nih.gov/OMIM</ext-link> (July 20, 2017)</comment>
</element-citation>
</ref>
<ref id="B155">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Phillips</surname>
<given-names>IR</given-names>
</name>
<name>
<surname>Shephard</surname>
<given-names>EA</given-names>
</name>
</person-group>
<year>2007</year>
<chapter-title>Primary Trimethylaminuria. 2007 Oct 8 [Updated 2015 Oct 1]. In: Pagon RA, Adam MP, Ardinger HH, <italic>et al.,</italic> editors</chapter-title>
<source/>GeneReviews® [Internet]
          <publisher-loc>Seattle (WA)</publisher-loc>
<publisher-name>University of Washington, Seattle</publisher-name>
<fpage>1993</fpage>
<lpage>2017</lpage>
<comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK1103/">https://www.ncbi.nlm.nih.gov/books/NBK1103/</ext-link> (November 01, 2017)</comment>
</element-citation>
</ref>
<ref id="B156">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Regier</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>CL</given-names>
</name>
</person-group>
<year>2000</year>
<chapter-title>Phenylalanine Hydroxylase Deficiency. 2000 Jan 10 [Updated 2017 Jan 5]. In: Pagon RA, Adam MP, Ardinger HH, <italic>et al.</italic>, editors</chapter-title>
<source/>GeneReviews® [Internet]
          <publisher-loc>Seattle (WA)</publisher-loc>
<publisher-name>University of Washington, Seattle</publisher-name>
<fpage>1993</fpage>
<lpage>2017</lpage>
<comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK1504/">https://www.ncbi.nlm.nih.gov/books/NBK1504/</ext-link> (November 01, 2017).</comment>
</element-citation>
</ref>
<ref id="B157">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Sniderman King</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Trahms</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>CR</given-names>
</name>
</person-group>
<year>2006</year>
<chapter-title>Tyrosinemia Type I. 2006 Jul 24 [Updated 2017 May 25]. In: Pagon RA, Adam MP, Ardinger HH, <italic>et al.</italic>, editors</chapter-title>
<source/>GeneReviews® [Internet]
          <publisher-loc>Seattle (WA)</publisher-loc>
<publisher-name>University of Washington, Seattle</publisher-name>
<fpage>1993</fpage>
<lpage>2017</lpage>
<comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK1515/">https://www.ncbi.nlm.nih.gov/books/NBK1515/</ext-link> (November 01, 2017)</comment>
</element-citation>
</ref>
<ref id="B158">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Seckington</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>L</given-names>
</name>
</person-group>
<year>2000</year>
<chapter-title>HFE-Associated Hereditary Hemochromatosis. 2000 Apr 3 [Updated 2015 Sep 17]. In: Pagon RA, Adam MP, Ardinger HH, <italic>et al.</italic>, editors</chapter-title>
<source/>GeneReviews® [Internet]
          <publisher-loc>Seattle (WA)</publisher-loc>
<publisher-name>University of Washington, Seattle</publisher-name>
<fpage>1993</fpage>
<lpage>2017</lpage>
<comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK1440">https://www.ncbi.nlm.nih.gov/books/NBK1440</ext-link> (November 01, 2017)</comment>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>